<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">J Neuropathol Exp Neurol</journal-id>
<journal-id journal-id-type="iso-abbrev">J. Neuropathol. Exp. Neurol</journal-id>
<journal-id journal-id-type="publisher-id">jnen</journal-id>
<journal-title-group>
<journal-title>Journal of Neuropathology and Experimental Neurology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0022-3069</issn>
<issn pub-type="epub">1554-6578</issn>
<publisher>
<publisher-name>Oxford University Press</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">32357373</article-id>
<article-id pub-id-type="pmc">7241941</article-id>
<article-id pub-id-type="doi">10.1093/jnen/nlaa024</article-id>
<article-id pub-id-type="publisher-id">nlaa024</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The <italic>MUC6/AP2A2</italic> Locus and Its Relevance to Alzheimer’s Disease: A Review</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Nelson</surname>
<given-names>Peter T</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="corresp" rid="nlaa024-cor1"></xref>
<xref ref-type="aff" rid="nlaa024-aff1">n1</xref>
<xref ref-type="aff" rid="nlaa024-aff2">n2</xref>
<!--<email>peter.nelson@uky.edu</email>-->
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fardo</surname>
<given-names>David W</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="nlaa024-aff1">n1</xref>
<xref ref-type="aff" rid="nlaa024-aff3">n3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Katsumata</surname>
<given-names>Yuriko</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="nlaa024-aff1">n1</xref>
<xref ref-type="aff" rid="nlaa024-aff3">n3</xref>
</contrib>
</contrib-group>
<aff id="nlaa024-aff1"><label>n1</label>
<institution>Sanders-Brown Center on Aging, University of Kentucky</institution>, Lexington, Kentucky</aff>
<aff id="nlaa024-aff2"><label>n2</label>
<institution>Department of Pathology, University of Kentucky</institution>, Lexington, Kentucky</aff>
<aff id="nlaa024-aff3"><label>n3</label>
<institution>Department of Biostatistics, University of Kentucky</institution>, Lexington, Kentucky</aff>
<author-notes>
<corresp id="nlaa024-cor1">Send correspondence to: Peter T. Nelson, MD, PhD, Rm 311 Sanders-Brown Center on Aging, 800 S. Limestone Avenue, Lexington, KY 40536; E-mail: <email>peter.nelson@uky.edu</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<month>6</month>
<year>2020</year>
</pub-date>
<pub-date iso-8601-date="2020-03-17" pub-type="epub">
<day>17</day>
<month>3</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>17</day>
<month>3</month>
<year>2020</year>
</pub-date>
<!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. -->
<volume>79</volume>
<issue>6</issue>
<fpage>568</fpage>
<lpage>584</lpage>
<history>
<date date-type="received">
<day>04</day>
<month>12</month>
<year>2019</year>
</date>
<date date-type="rev-recd">
<day>10</day>
<month>1</month>
<year>2020</year>
</date>
</history>
<permissions>
<copyright-statement>© 2020 American Association of Neuropathologists, Inc.</copyright-statement>
<copyright-year>2020</copyright-year>
<license license-type="cc-by-nc" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">
<license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License(<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</license-p>
</license>
</permissions>
<self-uri xlink:href="nlaa024.pdf"></self-uri>
<abstract>
<title>Abstract</title>
<p>We recently reported evidence of Alzheimer’s disease (AD)-linked genetic variation within the mucin 6 (<italic>MUC6</italic>) gene on chromosome 11p, nearby the adaptor-related protein complex 2 subunit alpha 2 (<italic>AP2A2</italic>) gene. This locus has interesting features related to human genomics and clinical research. <italic>MUC6</italic> gene variants have been reported to potentially influence viral—including herpesvirus—immunity and the gut microbiome. Within the <italic>MUC6</italic> gene is a unique variable number of tandem repeat (VNTR) region. We discovered an association between <italic>MUC6</italic> VNTR repeat expansion and AD pathologic severity, particularly tau proteinopathy. Here, we review the relevant literature. The AD-linked VNTR polymorphism may also influence <italic>AP2A2</italic> gene expression<italic>. AP2A2</italic> encodes a polypeptide component of the adaptor protein complex, AP-2, which is involved in clathrin-coated vesicle function and was previously implicated in AD pathogenesis. To provide background information, we describe some key knowledge gaps in AD genetics research. The “missing/hidden heritability problem” of AD is highlighted. Extensive portions of the human genome, including the <italic>MUC6</italic> VNTR, have not been thoroughly evaluated due to limitations of existing high-throughput sequencing technology. We present and discuss additional data, along with cautionary considerations, relevant to the hypothesis that <italic>MUC6</italic> repeat expansion influences AD pathogenesis.</p>
</abstract>
<kwd-group>
<kwd>Alzheimer’s Disease Sequencing Project (ADSP)</kwd>
<kwd>Amyloid</kwd>
<kwd>APOE</kwd>
<kwd>Copy number variation (CNV)</kwd>
<kwd>Endocytosis</kwd>
<kwd>Genome-wide association study (GWAS)</kwd>
<kwd>Whole-exome sequencing (WES)</kwd>
</kwd-group>
<funding-group>
<award-group award-type="grant">
<funding-source>
<institution-wrap>
<institution>National Institute on Aging</institution>
<institution-id institution-id-type="DOI">10.13039/100000049</institution-id>
</institution-wrap>
</funding-source>
<award-id>P30 AG028383</award-id>
<award-id>R01 AG057187</award-id>
<award-id>R01 AG042475</award-id>
<award-id>R56 AG057191</award-id>
<award-id>U01 AG016976</award-id>
</award-group>
<award-group award-type="grant">
<funding-source>
<institution-wrap>
<institution>National Institutes of Health</institution>
<institution-id institution-id-type="DOI">10.13039/100000002</institution-id>
</institution-wrap>
</funding-source>
</award-group>
<award-group award-type="grant">
<funding-source>
<institution-wrap>
<institution>NIH</institution>
<institution-id institution-id-type="DOI">10.13039/100000002</institution-id>
</institution-wrap>
</funding-source>
</award-group>
<award-group award-type="grant">
<funding-source>
<institution-wrap>
<institution>Common Fund of the Office of the Director of the NIH</institution>
</institution-wrap>
</funding-source>
</award-group>
<award-group award-type="grant">
<funding-source>
<institution-wrap>
<institution>NCI</institution>
<institution-id institution-id-type="DOI">10.13039/100000054</institution-id>
</institution-wrap>
</funding-source>
</award-group>
<award-group award-type="grant">
<funding-source>
<institution-wrap>
<institution>NHGRI</institution>
<institution-id institution-id-type="DOI">10.13039/100000051</institution-id>
</institution-wrap>
</funding-source>
</award-group>
<award-group award-type="grant">
<funding-source>
<institution-wrap>
<institution>NHLBI</institution>
<institution-id institution-id-type="DOI">10.13039/100000050</institution-id>
</institution-wrap>
</funding-source>
</award-group>
<award-group award-type="grant">
<funding-source>
<institution-wrap>
<institution>NIDA</institution>
<institution-id institution-id-type="DOI">10.13039/100000026</institution-id>
</institution-wrap>
</funding-source>
</award-group>
<award-group award-type="grant">
<funding-source>
<institution-wrap>
<institution>NIMH</institution>
<institution-id institution-id-type="DOI">10.13039/100000025</institution-id>
</institution-wrap>
</funding-source>
</award-group>
<award-group award-type="grant">
<funding-source>
<institution-wrap>
<institution>NINDS</institution>
<institution-id institution-id-type="DOI">10.13039/100000065</institution-id>
</institution-wrap>
</funding-source>
</award-group>
</funding-group>
<counts>
<page-count count="17"></page-count>
</counts>
</article-meta>
</front>
<body>
<sec>
<title>INTRODUCTION</title>
<p>This review article is about a putative Alzheimer’s disease (AD)-associated genetic polymorphism within the mucin 6 (<italic>MUC6</italic>) gene, and &lt;4000 base pairs (bp) away from the gene that encodes adaptor-related protein complex 2 subunit alpha 2 (<italic>AP2A2</italic>), on human chromosome 11p15.5 (<xref ref-type="bibr" rid="nlaa024-B1">1</xref>). The genomic locus of interest is a poorly annotated variable number of tandem repeat (VNTR) region, largely unreadable by conventional sequencing methods. Here, we review the topical literature on <italic>MUC6</italic>, the risk-associated polymorphic VNTR region, and <italic>AP2A2</italic>. We examine whether it is credible that a novel high-impact risk allele could be discovered, given that so many AD-linked genetic loci have already been identified. Evidence is provided in support of the hypothesis that <italic>MUC6</italic> VNTR repeat expansion is associated with AD risk. We also discuss reasons to be skeptical of the hypothesis. Relevant data are presented from the University of Kentucky AD Center (UK-ADC) autopsy cohort. Finally, critical knowledge gaps are highlighted.</p>
<sec>
<title>Mucin 6 (<italic>MUC6</italic>)</title>
<p>The <italic>MUC6</italic> gene is located in a recombination prone region approximately 1 million bp from the telomere of human chromosome 11p (<xref ref-type="bibr" rid="nlaa024-B2">2</xref>, <xref ref-type="bibr" rid="nlaa024-B3">3</xref>). <italic>MUC6</italic> is clustered along with 3 other mucin family genes (<italic>MUC2</italic>, <italic>MUC5A</italic>, and <italic>MUC5B</italic>) and <italic>AP2A2</italic>. <italic>MUC6</italic> and <italic>AP2A2</italic> are in close proximity, oriented in opposite directions—their 3′-untranslated regions nearly overlap (<xref ref-type="fig" rid="nlaa024-F1">Fig. 1</xref>). The juxtaposition of <italic>AP2A2</italic> and <italic>MUC6</italic>, with possible sharing of 3′ regulatory sequence elements, is conserved on chromosomes of other vertebrates including frogs (<italic>Xenopus</italic> <italic>tropicalis</italic>).</p>
<fig id="nlaa024-F1" orientation="portrait" position="float">
<label>FIGURE 1.</label>
<caption>
<p>The region on human chromosome 11 which contains the <italic>MUC6</italic> variable number of tandem repeat (VNTR) region. This locus is ∼1 million bp from the chromosome 11p telomere. The window of human chromosome 11p15.5 shown here<bold> (A)</bold> is relatively small (&lt;24 kb) and contains only the 3′ portions of both <italic>AP2A2</italic> and <italic>MUC6</italic> genes. The yellow arrow indicates the <italic>MUC6</italic> exon 31 which contains the VNTR region. Note that, in this annotated assembly, the <italic>MUC6</italic> Exon 31 is &lt;4 kb in size, although the actual <italic>MUC6</italic> exon 31 is usually &gt;10 kb (often &gt;15 kb). This underscores the extremely incomplete annotation for this VNTR-containing exon. Source: <ext-link ext-link-type="uri" xlink:href="https://genome.ucsc.edu/">https://genome.ucsc.edu/</ext-link>. Panel <bold>(B)</bold> provides a selective overview of previously reported findings related to <italic>MUC6</italic> exon 31. Panel <bold>(C)</bold> depicts, in cartoon form, the distinction between single-nucleotide variants (SNVs) and variation in a VNTR region. Individual SNVs are by definition small (usually 1 bp), whereas VNTR regions’ tandem repeat expansion can lead to a much larger change in the local genomic architecture. For the <italic>MUC6</italic> VNTR region, each repeat unit is ∼507 bp in length. </p>
</caption>
<graphic xlink:href="nlaa024f1"></graphic>
</fig>
<p>Mucin genes encode proteins that become glycosylated and serve as gel-like substances to protect and lubricate epithelial surfaces (<xref ref-type="bibr" rid="nlaa024-B4">4</xref>). The MUC6 protein is expressed preferentially in the gastrointestinal (GI) tract, and also in genitourinary and pulmonary epithelia (<xref ref-type="bibr" rid="nlaa024-B5">5–9</xref>). Here, we will focus on the repetitive domains and gene expression regulation of <italic>MUC6</italic>, as may be relevant to the hypothesis that the <italic>MUC6</italic> VNTR is an AD risk allele.</p>
<p>A conspicuous feature of the mucin gene family is that long repetitive genetic sequences reside in exons, and are transcribed and translated into proteins (<xref ref-type="bibr" rid="nlaa024-B10">10</xref>). The repetitive DNA regions encode polypeptide motifs enriched with residues for O-linked glycosylation—proline, threonine, and serine amino acids, thus, they are termed PTS domains. These glycosylated polypeptides help constitute the “gel forming” components of mucus (<xref ref-type="bibr" rid="nlaa024-B10">10</xref>).</p>
<p>Another interesting characteristic of the mucin gene family is that the different mucin genes’ expression may be subject to orchestrated regulation by inflammation-related transcription factors (<xref ref-type="bibr" rid="nlaa024-B11">11</xref>). In cells transcribing the mucin genes clustered together on chromosome 11p15.5, the local chromatin forms three-dimensional structures for coordinated exposure of multiple mucin genes’ transcriptional promoter sequences (<xref ref-type="bibr" rid="nlaa024-B12">12</xref>). These interactions are complicated (<xref ref-type="bibr" rid="nlaa024-B13">13</xref>) and context-specific: In various inflammatory diseases, there is differential regulation of chromosome 11p15.5 mucin genes’ expression (<xref ref-type="bibr" rid="nlaa024-B14">14–17</xref>).</p>
<p>
<italic>MUC6</italic> transcripts are expressed at very low levels in human brain (<xref ref-type="fig" rid="nlaa024-F2">Fig. 2</xref>). However, MUC6 protein function may have an impact on the brain. There is increasing appreciation of brain-gut interactions, which may theoretically be affected by the microbiome—that is, intestinal bacteria. Mucins, including <italic>MUC6</italic>, constitute a barrier for intestinal organisms: <italic>MUC6</italic> has been reported to block <italic>Helicobacter</italic> <italic>pylori</italic> infections (<xref ref-type="bibr" rid="nlaa024-B18">18</xref>, <xref ref-type="bibr" rid="nlaa024-B19">19</xref>), and mucin proteins play similar functions in altering risk for other bacterial and viral infections (<xref ref-type="bibr" rid="nlaa024-B4">4</xref>, <xref ref-type="bibr" rid="nlaa024-B20">20–22</xref>). The intestinal microbiome may play mechanistic roles in neurodegeneration, including AD (<xref ref-type="bibr" rid="nlaa024-B23">23–25</xref>); therefore, a microbiome-modulating gene may affect AD indirectly.</p>
<fig id="nlaa024-F2" orientation="portrait" position="float">
<label>FIGURE 2.</label>
<caption>
<p>Screenshots from the Genotype-Tissue Expression (GTEx) data set depicting human tissue-specific gene expression patterns for <italic>MUC6</italic> <bold>(A)</bold> and <italic>AP2A2</italic> <bold>(B).</bold> Note that <italic>MUC6</italic> is expressed strongly in stomach tissue but not appreciably in the CNS (yellow bars). By contrast, <italic>AP2A2</italic> is expressed at high levels in CNS tissue. The source of the data for these figures was the GTEx Portal, <ext-link ext-link-type="uri" xlink:href="https://gtexPortal.org">https://gtexportal.org</ext-link>. This figure was adapted from Katsumata et al (<xref ref-type="bibr" rid="nlaa024-B1">1</xref>), with permission.</p>
</caption>
<graphic xlink:href="nlaa024f2"></graphic>
</fig>
<p>
<italic>MUC6</italic> may also influence susceptibility to non-GI viral infection, which in theory could be relevant to AD risk. There is a body of literature supporting the hypothesis that AD is caused or exacerbated by viral, particularly herpesvirus, infection (<xref ref-type="bibr" rid="nlaa024-B26">26–29</xref>). In a recent study by Readhead et al (<xref ref-type="bibr" rid="nlaa024-B30">30</xref>), herpesviruses’ genetic imprints were increased in AD brains. Readhead et al also performed a genome-wide association study (GWAS) to assess the associative impact of human genetic variants on vulnerability to brain infection by herpesviruses (<xref ref-type="bibr" rid="nlaa024-B30">30</xref>). Remarkably, the human genetic variant “associated with the most viruses… (rs71454075) falls within the glycoprotein mucin 6” (<xref ref-type="bibr" rid="nlaa024-B30">30</xref>)—and, this virus-associated polymorphism resides in the <italic>MUC6</italic> VNTR region. <italic>MUC6</italic> gene variation was also associated with vulnerability to respiratory syncytial virus infection (<xref ref-type="bibr" rid="nlaa024-B31">31</xref>). The association(s) between AD and infectious disease are hypothetical and controversial (see, e.g., [<xref ref-type="bibr" rid="nlaa024-B32">32</xref>]). However, the prior published findings suggest that complex processes related to the gut microbiome and/or viral immunity may be modulated by <italic>MUC6</italic>. It is unknown whether the regulation of <italic>MUC6</italic> gene expression affects or is affected by expression of the nearby gene, <italic>AP2A2</italic>.</p>
</sec>
<sec>
<title>Adaptor-Related Protein Complex 2 Subunit Alpha 2 (<italic>AP2A2)</italic></title>
<p>In contrast to <italic>MUC6, AP2A2</italic> is transcribed robustly in many human tissues including the brain (<xref ref-type="fig" rid="nlaa024-F2">Fig. 2</xref>). The AP2A2 polypeptide is a component of the adaptor protein complex, AP-2 (<xref ref-type="bibr" rid="nlaa024-B33">33</xref>, <xref ref-type="bibr" rid="nlaa024-B34">34</xref>), a 4-protein multimer that is located on a subset of endocytic vesicles (<xref ref-type="bibr" rid="nlaa024-B35">35</xref>, <xref ref-type="bibr" rid="nlaa024-B36">36</xref>). This is an evolutionarily ancient protein complex and the <italic>AP2A2</italic> gene has conserved orthologs in plants, fungi, and invertebrates (<xref ref-type="bibr" rid="nlaa024-B37">37</xref>). Functionally, AP-2 participates in assembling the components of early clathrin-coated vesicles (CCVs) at the plasma membrane (<xref ref-type="bibr" rid="nlaa024-B33">33</xref>, <xref ref-type="bibr" rid="nlaa024-B35">35</xref>, <xref ref-type="bibr" rid="nlaa024-B38">38</xref>) (<xref ref-type="fig" rid="nlaa024-F3">Fig. 3</xref>). The AP-2 complex interacts directly with lipids, clathrin, “cargos” that are undergoing CCV-mediated endocytosis, and accessory CCV proteins such as PICALM and BIN1 (<xref ref-type="bibr" rid="nlaa024-B39">39–41</xref>).</p>
<fig id="nlaa024-F3" orientation="portrait" position="float">
<label>FIGURE 3.</label>
<caption>
<p>Clathrin-coated vesicle (CCV) formation at the plasma membrane involves late-onset Alzheimer’s disease (AD) risk-associated gene products including BIN1 and PICALM proteins. The CCV is here shown in early stage of formation at the plasma membrane. Clathrin is depicted with a dashed line. The AP2A2 protein is a component of the AP-2 adapter complex which is located on the plasma membrane and then on CCVs as the vesicle is internalized. Protein cargos that may be related to AD pathogenesis, including Tau, APP, BACE1, APOE, and various viruses have been reported to be processed via CCV-mediated endocytosis. Other (non-CCV) endocytosis mechanisms also occur for some of these proteins. For this cartoon, some relevant structures were minimized for the sake of clarity.</p>
</caption>
<graphic xlink:href="nlaa024f3"></graphic>
</fig>
<p>Cargos for CCV-mediated endocytic internalization via AP-2 have been reported to include the amyloid precursor protein (APP), beta-site APP cleaving enzyme 1 (BACE1), Tau, synaptic vesicle proteins, and many others (<xref ref-type="bibr" rid="nlaa024-B33">33</xref>, <xref ref-type="bibr" rid="nlaa024-B35">35</xref>, <xref ref-type="bibr" rid="nlaa024-B41">41–47</xref>). It also has been proposed that the apolipoprotein E (APOE) protein and lipoprotein receptors are internalized via CCV endocytosis (<xref ref-type="bibr" rid="nlaa024-B43">43</xref>, <xref ref-type="bibr" rid="nlaa024-B48">48–50</xref>). There is an extensive literature documenting the roles of CCV endocytosis and AP-2 in viral infection (<xref ref-type="bibr" rid="nlaa024-B51">51–54</xref>). In sum, AP2A2 function may tie in with multiple mechanisms linked to AD pathogenesis.</p>
<p>AP-2 is a stable protein complex comprising 4 domains, which are termed alpha, beta, mu, and sigma (<xref ref-type="bibr" rid="nlaa024-B39">39</xref>). <italic>AP2A1</italic> and <italic>AP2A2</italic> are homologous human genes that encode the alpha subunit of the AP-2 complex. Relatively little is known about the molecular neurobiology of <italic>AP2A2</italic> <italic>per se</italic>. Publicly accessible databases indicate that the <italic>AP2A2</italic> transcript is expressed in a broad range of CNS cell lineages (data not shown). At the tissue level, both <italic>AP2A1</italic> and <italic>AP2A2</italic> are highly expressed in human cerebellum, but <italic>AP2A2</italic> is expressed at lower levels in the cerebral cortex according to the GTEx Portal (<ext-link ext-link-type="uri" xlink:href="https://gtexPortal.org/">https://gtexportal.org/</ext-link> [<xref ref-type="bibr" rid="nlaa024-B55">55</xref>]); <xref ref-type="fig" rid="nlaa024-F4">Figure 4</xref>. These findings are intriguing because the cerebellum is relatively resistant to AD-type pathology (<xref ref-type="bibr" rid="nlaa024-B56">56</xref>, <xref ref-type="bibr" rid="nlaa024-B57">57</xref>).</p>
<fig id="nlaa024-F4" orientation="portrait" position="float">
<label>FIGURE 4.</label>
<caption>
<p>Screenshots from the Genotype-Tissue Expression (GTEx) data set depicting human CNS gene expression for the adapter complex (AP-2) alpha subunit-encoding gene transcripts, <italic>AP2A2</italic> <bold>(A)</bold> and <italic>AP2A1</italic> <bold>(B)</bold>. These 2 genes encode proteins homologous in sequence—80.2% identity and 90.3% similar according to <ext-link ext-link-type="uri" xlink:href="https://embnet.vital-it.ch/software/LALIGN_form.html">https://embnet.vital-it.ch/software/LALIGN_form.html</ext-link>. Both genes’ transcripts are expressed at high levels in the cerebellum (red asterisks), but the <italic>AP2A1</italic> (compared to the <italic>AP2A2</italic> transcripts) are expressed at higher levels in the cerebral cortex (green asterisks). Implications of this difference are not known; there have been relatively few studies of <italic>AP2A2</italic> expression regulation in the human brain. BA, Brodmann area. The source for these figures was the GTEx Portal, <ext-link ext-link-type="uri" xlink:href="https://gtexPortal.org">https://gtexportal.org</ext-link>.</p>
</caption>
<graphic xlink:href="nlaa024f4"></graphic>
</fig>
<p>We performed immunohistochemical staining for AP2A2 in human brains. In nondemented control brains, AP2A2 immunoreactivity showed a punctate pattern in neurons, consistent with CCV/vesicular structures (<xref ref-type="bibr" rid="nlaa024-B1">1</xref>). In AD brains, AP2A2 colocalized with phospho-tau-immunoreactive neurofibrillary tangles (NFTs); by contrast, AP2A2 colocalization with phospho-tau was not seen in progressive supranuclear palsy (PSP)-tufted astrocytes (<xref ref-type="fig" rid="nlaa024-F5">Fig. 5</xref>). Intriguingly, a prior study reported a similar immunostaining pattern using an antibody against CCV-associated protein PICALM—the PICALM protein also was colocalized with phospho-tau in AD NFTs but not with tufted astrocytes in PSP (<xref ref-type="bibr" rid="nlaa024-B58">58</xref>).</p>
<fig id="nlaa024-F5" orientation="portrait" position="float">
<label>FIGURE 5.</label>
<caption>
<p>Photomicrographs of human brain (aged control <bold>[A–C]</bold>, Alzheimer’s disease <bold>[D–F]</bold>, and progressive supranuclear palsy [PSP; <bold>G–I</bold>]) show the colocalization of AP2A2 protein with phospho-tau-immunoreactive neurofibrillary tangles of Alzheimer’s disease. Panels <bold>(C)</bold>, <bold>(F)</bold>, and <bold>(I)</bold> have merged staining results combined with blue DAPI counterstain to visualize cell nuclei. AP2A2-immunoreactive cells are seen in aged control brain but are not colocalized with phospho-tau <bold>(A–C)</bold>. In Alzheimer’s disease cerebral neocortex, there was a strong tendency for colocalization of an accentuated AP2A2 signal <bold>(D)</bold> that colocalized with phospho-tau <bold>(E)</bold>; see yellow arrows. By contrast, cells that were immunonegative for phospho-tau tangles (blue arrow) had less AP2A2 immunoreactivity. In PSP basal ganglia, the phospho-tau immunoreactivity (yellow arrowheads) in tufted astrocytes did not colocalize with AP2A2 immunoreactivity. The colocalization was quantified and methods published in detail in (<xref ref-type="bibr" rid="nlaa024-B1">1</xref>). Thanks to Dr Peter Davies for the anti-phospho-tau (PHF-1) monoclonal antibody. Scale bars = 100 μM.</p>
</caption>
<graphic xlink:href="nlaa024f5"></graphic>
</fig>
<p>As to the impact of <italic>AP2A2</italic> genetic variation, prior GWAS have linked <italic>AP2A2</italic> gene variants with AD risk—yet not conclusively (<xref ref-type="table" rid="nlaa024-T1">Tables 1</xref> and <xref ref-type="table" rid="nlaa024-T2">2</xref>). (By convention, we refer to single nucleotide polymorphisms as SNPs if there is common variability at that locus in human populations and, more generally, as single nucleotide variants [SNVs] if the minor allele is &lt;1% prevalent [<xref ref-type="bibr" rid="nlaa024-B59">59</xref>]). A common <italic>AP2A2</italic> SNP (rs10751667) was listed as a “suggestive” AD-linked allele in a large, meta-analytic GWAS: nominal p∼6 × 10<sup>−7</sup> association with the AD phenotype, not statistically significant after correcting for multiple comparisons (<xref ref-type="bibr" rid="nlaa024-B60">60</xref>) (<xref ref-type="table" rid="nlaa024-T1">Table 1</xref>). In a separate study, the same SNP (rs10751667) was associated with a subtype of mild cognitive impairment (<xref ref-type="bibr" rid="nlaa024-B61">61</xref>). Another recent GWAS reported a different <italic>AP2A2</italic> SNP, rs10794342, again with suggestive nominal (p∼4 × 10<sup>−6</sup>) association with AD risk (<xref ref-type="bibr" rid="nlaa024-B62">62</xref>) (<xref ref-type="table" rid="nlaa024-T1">Table 1</xref>).</p>
<table-wrap id="nlaa024-T1" orientation="portrait" position="float">
<label>TABLE 1.</label>
<caption>
<p>
<italic>AP2A2</italic> Single Nucleotide Polymorphisms (SNPs) That Showed “Suggestive” Nominal Association With Alzheimer’s Disease (AD) Phenotype in Genome-Wide Association Studies (GWAS), Along With Expression Quantitative Trait Locus (eQTL) Status<xref ref-type="table-fn" rid="tblfn1">*</xref></p>
</caption>
<table frame="hsides" rules="groups">
<colgroup span="1">
<col align="left" span="1" valign="top"/>
<col align="char" char="(" span="1" valign="top"/>
<col align="center" span="1" valign="top"/>
<col align="left" span="1" valign="top"/>
<col align="center" span="1" valign="top"/>
<col align="center" span="1" valign="top"/>
</colgroup>
<thead>
<tr>
<th colspan="1" rowspan="1">
<italic>AP2A2</italic> SNP With Nominal GWAS Association With the AD Phenotype</th>
<th align="center" colspan="1" rowspan="1">Reference</th>
<th colspan="1" rowspan="1">Nominal p Value for Association With AD Phenotype</th>
<th colspan="1" rowspan="1">AD Association Statistically Significant After Correction for Multiple Comparisons?</th>
<th colspan="1" rowspan="1">eQTL for <italic>AP2A2?</italic><xref ref-type="table-fn" rid="tblfn1">*</xref></th>
<th colspan="1" rowspan="1">eQTL for <italic>MUC6?</italic><xref ref-type="table-fn" rid="tblfn1">*</xref></th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="1" rowspan="1">rs10751667</td>
<td colspan="1" rowspan="1">Lambert et al (<xref ref-type="bibr" rid="nlaa024-B60">60</xref>)</td>
<td colspan="1" rowspan="1">p = 6.3 × 10<sup>−7</sup></td>
<td align="center" colspan="1" rowspan="1">No</td>
<td colspan="1" rowspan="1">Yes; p = 5.7 × 10<sup>−30</sup>*</td>
<td colspan="1" rowspan="1">Yes; p = 2.9 × 10<sup>−35</sup>*</td>
</tr>
<tr>
<td colspan="1" rowspan="1">rs10794342</td>
<td colspan="1" rowspan="1">Nazarian et al (<xref ref-type="bibr" rid="nlaa024-B62">62</xref>)</td>
<td colspan="1" rowspan="1">p = 4.4 × 10<sup>−6</sup></td>
<td align="center" colspan="1" rowspan="1">No</td>
<td colspan="1" rowspan="1">Yes; p = 5.9 × 10<sup>−40</sup>*</td>
<td colspan="1" rowspan="1">No<xref ref-type="table-fn" rid="tblfn1">*</xref></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="tblfn1">
<label>*</label>
<p>eQTL status and p values indicated were according to “Multiple Tissue eQTL Comparison Meta Analysis RE2” at GTEx Portal, <ext-link ext-link-type="uri" xlink:href="https://gtexPortal.org/">https://gtexportal.org/</ext-link>. For details on the methods and numbers of samples involved in the GTEx work, see <ext-link ext-link-type="uri" xlink:href="https://gtexPortal.org/home/documentationPage#staticTextAnalysisMethods">https://gtexportal.org/home/documentationPage#staticTextAnalysisMethods</ext-link>.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="nlaa024-T2" orientation="portrait" position="float">
<label>TABLE 2.</label>
<caption>
<p>
<italic>AP2A2</italic> Single Nucleotide Polymorphisms (SNPs) From <xref ref-type="table" rid="nlaa024-T1">Table 1</xref> in More Recent Alzheimer’s Disease GWAS With Larger (but still overlapping) Samples</p>
</caption>
<table frame="hsides" rules="groups">
<colgroup span="1">
<col align="left" span="1" valign="top"/>
<col align="center" span="1" valign="top"/>
<col align="center" span="1" valign="top"/>
<col align="center" span="1" valign="top"/>
</colgroup>
<thead>
<tr>
<th colspan="1" rowspan="2">Reference</th>
<th colspan="2" rowspan="1">Kunkle et al (<xref ref-type="bibr" rid="nlaa024-B64">64</xref>)<hr/></th>
<th colspan="1" rowspan="2">Jansen et al (<xref ref-type="bibr" rid="nlaa024-B63">63</xref>)</th>
</tr>
<tr>
<th colspan="1" rowspan="1">Stage 1</th>
<th colspan="1" rowspan="1">Stage 2</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="1" rowspan="1">Sample size, n</td>
<td colspan="1" rowspan="1">63 926<xref ref-type="table-fn" rid="tblfn2">*</xref></td>
<td colspan="1" rowspan="1">18 845<xref ref-type="table-fn" rid="tblfn2">*</xref></td>
<td colspan="1" rowspan="1">455 258<xref ref-type="table-fn" rid="tblfn2">*</xref><sup>,</sup><xref ref-type="table-fn" rid="tblfn3"><sup>†</sup></xref></td>
</tr>
<tr>
<td colspan="1" rowspan="1">rs10751667</td>
<td colspan="1" rowspan="1">1.4 × 10<sup>−4</sup><xref ref-type="table-fn" rid="tblfn4"><sup>‡</sup></xref></td>
<td colspan="1" rowspan="1">2.2 × 10<sup>−6</sup><xref ref-type="table-fn" rid="tblfn4"><sup>‡</sup></xref></td>
<td colspan="1" rowspan="1">7.5 × 10<sup>−3</sup><xref ref-type="table-fn" rid="tblfn4"><sup>‡</sup></xref></td>
</tr>
<tr>
<td colspan="1" rowspan="1">rs10794342</td>
<td colspan="1" rowspan="1">3.6 × 10<sup>−4</sup><xref ref-type="table-fn" rid="tblfn4"><sup>‡</sup></xref></td>
<td colspan="1" rowspan="1">9.2 × 10<sup>−5</sup><xref ref-type="table-fn" rid="tblfn4"><sup>‡</sup></xref></td>
<td colspan="1" rowspan="1">7.2 × 10<sup>−3</sup><xref ref-type="table-fn" rid="tblfn4"><sup>‡</sup></xref></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="tblfn2">
<label>*</label>
<p>Overlapping samples with Lambert et al (<xref ref-type="bibr" rid="nlaa024-B60">60</xref>).</p>
</fn>
<fn id="tblfn3">
<label></label>
<p>
<sup>†</sup>The Jansen et al study included 47 493 Alzheimer’s disease “proxy” cases and 328 320 “proxy” controls as determined by reported parental family history.</p>
</fn>
<fn id="tblfn4">
<label></label>
<p>
<sup>‡</sup>Nominal p values from summary data are shown; these were not statistically significant after correcting for multiple comparisons.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Larger, meta-analytic AD GWAS have been published in the past few years. We highlight the results of studies by Jansen et al (<xref ref-type="bibr" rid="nlaa024-B63">63</xref>) and Kunkle et al (<xref ref-type="bibr" rid="nlaa024-B64">64</xref>), for which we obtained summary statistics (<xref ref-type="table" rid="nlaa024-T2">Table 2</xref>). Again, the associations between <italic>AP2A2</italic> SNPs and the AD phenotype were nominally statistically significant, and with the same risk alleles as in prior reports. A similar finding was reported in the study by Marioni et al (<xref ref-type="bibr" rid="nlaa024-B65">65</xref>) (data not shown), but this study sample (the included cases and controls) was highly similar to the later Jansen et al (<xref ref-type="bibr" rid="nlaa024-B63">63</xref>) study, for which results are shown in <xref ref-type="table" rid="nlaa024-T2">Table 2</xref>. More generally, evaluating the abovementioned GWAS independently of each other is not possible via summary statistics because all of these GWAS samples had some degree of overlap.</p>
<p>The 2 marginal AD-associated SNPs (rs10751667 and rs10794342) are in moderate linkage disequilibrium (LD) with each other (D’ = 0.99, r<sup>2</sup> = 0.58 in “all populations” according to <ext-link ext-link-type="uri" xlink:href="http://ldlink.nci.nih.gov">ldlink.nci.nih.gov</ext-link>), which means that their genetic variants tend to be co-inherited. In the Nazarian et al (<xref ref-type="bibr" rid="nlaa024-B62">62</xref>) and Lambert et al (<xref ref-type="bibr" rid="nlaa024-B60">60</xref>) papers, the less common alleles were protective (OR = 0.82 and OR = 0.93, respectively). Variation of both rs10751667 and rs10794342 SNPs is associated with altered expression for <italic>AP2A2</italic>, i.e., both are <italic>AP2A2</italic> expression quantitative trait loci (eQTL), whereas rs10751667 is also an eQTL for <italic>MUC6</italic>. <xref ref-type="table" rid="nlaa024-T1">Table 1</xref> shows results from the GTEx Portal website describing meta-analyses of data derived from CNS and non-CNS tissues. As an example of results from brain tissue, according to the GTEx Portal, the rs10794342_T allele is associated with lower <italic>AP2A2</italic> expression in human cerebellum (p &lt; 1 x 10<sup>−7</sup> based on the analysis of 209 brain samples). It is an intriguing possibility that a particular polymorphism or haplotype is a risk allele for AD and also could alter expression levels for both <italic>AP2A2</italic> and <italic>MUC6</italic>. The GTEx Portal indicates that rs10794342 and rs10751667 SNPs are also associated with alternative <italic>AP2A2</italic> splicing—thus, are sQTLs for <italic>AP2A2</italic>—in specific human tissues (data not shown), another phenomenon that may merit further study. The SNPs shown in <xref ref-type="table" rid="nlaa024-T1">Table 1</xref> are &lt;75 kbp away from the <italic>MUC6</italic> VNTR region, and are in LD with SNPs in the <italic>MUC6</italic> VNTR region (data not shown). Thus, it is possible that the AD-linked <italic>AP2A2</italic> SNPs are a “flag” (proxy feature) for the status of the <italic>MUC6</italic> VNTR.</p>
<p>Additional published data have provided suggestive links between <italic>AP2A2</italic> gene variants and the AD phenotype. A recent GWAS of brain transcriptomic and splicing data, correlating with AD phenotype data, reported that transcript expression variability for both <italic>AP2A2</italic> and the homologous <italic>AP2A1</italic> gene was associated with the AD phenotype (<xref ref-type="bibr" rid="nlaa024-B66">66</xref>). A separate study analyzed AD GWAS and transcriptomic data and found that <italic>AP2A2</italic> was a “potential disease-causal” gene (<xref ref-type="bibr" rid="nlaa024-B67">67</xref>). Further, in a large, inbred Amish family with genetic risk for AD that was independent of <italic>APOE</italic>, a genomic screen showed that the genetic marker most strongly associated with the AD phenotype (highest multipoint logarithmic of the odds, or LOD, score) was located &lt;500 kb from <italic>AP2A2</italic> on chromosome 11p (<xref ref-type="bibr" rid="nlaa024-B68">68</xref>).</p>
<p>Variants of other genes that encode CCV-related proteins have been repeatedly associated with late-onset AD risk (<xref ref-type="bibr" rid="nlaa024-B58">58</xref>, <xref ref-type="bibr" rid="nlaa024-B69">69–72</xref>) (<xref ref-type="fig" rid="nlaa024-F3">Fig. 3</xref>). In a recent large GWAS that incorporated many different study cohorts, <italic>PICALM</italic> and <italic>BIN1</italic> gene variants were the non-<italic>APOE</italic> risk alleles with the lowest p values (<xref ref-type="bibr" rid="nlaa024-B73">73</xref>). PICALM and BIN1 proteins have also been implicated in Tau proteinopathy and in APP/Aβ processing (<xref ref-type="bibr" rid="nlaa024-B40">40–42</xref>, <xref ref-type="bibr" rid="nlaa024-B58">58</xref>, <xref ref-type="bibr" rid="nlaa024-B74">74–77</xref>). Additional endocytic genes—for example, <italic>SORL1</italic> and <italic>CD2AP</italic>—were also associated with APP processing, autophagy, and clinical dementia (<xref ref-type="bibr" rid="nlaa024-B71">71</xref>, <xref ref-type="bibr" rid="nlaa024-B72">72</xref>, <xref ref-type="bibr" rid="nlaa024-B78">78</xref>). Taken together, these results provide theoretical support for the hypothesis that a gene variant which affects AP-2/CCV function could have an impact on AD risk.</p>
</sec>
<sec>
<title>The <italic>MUC6</italic> VNTR</title>
<p>The term VNTR describes repetitive end-to-end iterations of genomic sequences ≥6 bp in length (<xref ref-type="bibr" rid="nlaa024-B79">79</xref>, <xref ref-type="bibr" rid="nlaa024-B80">80</xref>). The number of repeat units is inherited in the germline and often differs from individual to individual (<xref ref-type="bibr" rid="nlaa024-B79">79</xref>, <xref ref-type="bibr" rid="nlaa024-B81">81</xref>). There is a wide variety of VNTR sequences in the human genome (<xref ref-type="bibr" rid="nlaa024-B79">79</xref>). We note that the genomic segment we are referring to as a VNTR region could also be referred to as a copy number variant (<xref ref-type="bibr" rid="nlaa024-B82">82</xref>, <xref ref-type="bibr" rid="nlaa024-B83">83</xref>), structural variant (<xref ref-type="bibr" rid="nlaa024-B84">84</xref>, <xref ref-type="bibr" rid="nlaa024-B85">85</xref>), satellite DNA (<xref ref-type="bibr" rid="nlaa024-B86">86</xref>), insertions/deletions (<xref ref-type="bibr" rid="nlaa024-B87">87</xref>), simple sequence repeats (<xref ref-type="bibr" rid="nlaa024-B88">88</xref>), or tandem repeat expansion, according to different sources. The larger (with more repeats) versions of many different tandemly repeated sequences in the human genome have been associated with neurologic diseases (<xref ref-type="bibr" rid="nlaa024-B89">89</xref>), and VNTRs can be transcriptional regulators for nearby genes (<xref ref-type="bibr" rid="nlaa024-B90">90</xref>). In the case of the <italic>C9ORF72</italic> tandem repeat expansion, now known to be a strong neurodegenerative disease genetic risk factor (<xref ref-type="bibr" rid="nlaa024-B91">91</xref>), the existence of that tandem repeat expansion was signaled by GWAS that identified nearby coinherited SNPs (<xref ref-type="bibr" rid="nlaa024-B92">92–94</xref>). Those SNPs are not themselves pathogenetic but they served as proxies to flag the disease-causing tandem repeat locus.</p>
<p>Other investigators have studied the <italic>MUC6</italic> VNTR region (<xref ref-type="bibr" rid="nlaa024-B95">95–101</xref>). No other known human tandem repeat sequence is highly similar to the <italic>MUC6</italic> VNTR region. Most human genome VNTR regions contain repeated sequences that are shorter (usually 10–60 bp) than those in the <italic>MUC6</italic> gene (<xref ref-type="bibr" rid="nlaa024-B80">80</xref>). By contrast, the tandemly repeated sequences in <italic>MUC6</italic> are ∼507 bp each, and these unit repeats are composed of PTS-encoding subunits (<xref ref-type="bibr" rid="nlaa024-B79">79</xref>, <xref ref-type="bibr" rid="nlaa024-B95">95</xref>, <xref ref-type="bibr" rid="nlaa024-B101">101</xref>). The number of ∼507-bp repeat sequences in the human <italic>MUC6</italic> VNTR region is usually between 15 and 36 repeats (<xref ref-type="fig" rid="nlaa024-F1">Fig. 1</xref>): In ∼95% of cases, the <italic>MUC6</italic> VNTR region’s size ranges between 7.5 and 18 kb (<xref ref-type="bibr" rid="nlaa024-B19">19</xref>, <xref ref-type="bibr" rid="nlaa024-B98">98</xref>). <italic>MUC6</italic> PTS domain-encoding DNA sequences are highly polymorphic (sequences differ between human individuals), causing one group to hypothesize that “the actual amino acid sequence is less important as long as it contains a sufficient number of anchor sites for O-glycans…” (<xref ref-type="bibr" rid="nlaa024-B95">95</xref>).</p>
<p>Because of the known GI tissue expression of <italic>MUC6</italic>, a major focus in prior work has been on how the <italic>MUC6</italic> tandem repeat polymorphisms are associated with risk for GI diseases—mainly cancer and infection (<xref ref-type="bibr" rid="nlaa024-B19">19</xref>, <xref ref-type="bibr" rid="nlaa024-B96">96</xref>, <xref ref-type="bibr" rid="nlaa024-B102">102</xref>, <xref ref-type="bibr" rid="nlaa024-B103">103</xref>). Findings from these previous studies indicated that the short version(s) of the <italic>MUC6</italic> VNTR was the risk alleles, in contrast to what we reported in AD (<xref ref-type="bibr" rid="nlaa024-B19">19</xref>, <xref ref-type="bibr" rid="nlaa024-B99">99</xref>). Interestingly, minisatellite polymorphisms outside of exon 31 were also located in and near the <italic>MUC6</italic> gene, and were associated with <italic>MUC6</italic> expression (<xref ref-type="bibr" rid="nlaa024-B96">96</xref>, <xref ref-type="bibr" rid="nlaa024-B103">103</xref>). Many other studies have evaluated <italic>MUC6</italic> as a pathologic biomarker in human diseases, but most did not address tandem repeat polymorphism per se.</p>
<p>Unfortunately, the <italic>MUC6</italic> VNTR region is extremely difficult to sequence. This difficulty stems from technical factors, related to the size, number, and interindividual differences of the tandem repeats, as well as the incomplete annotation of the gene (<xref ref-type="bibr" rid="nlaa024-B95">95</xref>). There has not been a full-length <italic>MUC6</italic> transcript sequence reported to date (partial cDNA sequences have been described) (<xref ref-type="bibr" rid="nlaa024-B7">7</xref>, <xref ref-type="bibr" rid="nlaa024-B10">10</xref>, <xref ref-type="bibr" rid="nlaa024-B97">97</xref>, <xref ref-type="bibr" rid="nlaa024-B100">100</xref>, <xref ref-type="bibr" rid="nlaa024-B104">104</xref>). The technical difficulty in sequencing also applies to DNA haplotypes (<xref ref-type="bibr" rid="nlaa024-B79">79</xref>, <xref ref-type="bibr" rid="nlaa024-B95">95</xref>). The annotated GRCh37/GRCh38 reference panel sequences of the <italic>MUC6</italic> VNTR-related haplotypes were imperfectly stitched together (<xref ref-type="bibr" rid="nlaa024-B95">95</xref>), and both the reference (<xref ref-type="fig" rid="nlaa024-F1">Fig. 1</xref>) and the alternate contigs (i.e., the standard annotation sequences) are too small, not necessarily representative of any individual, much less a population’s repertoire.</p>
<p>In the Alzheimer’s Disease Sequencing Project (ADSP) whole-exome sequencing (WES) data set (<xref ref-type="bibr" rid="nlaa024-B105">105</xref>, <xref ref-type="bibr" rid="nlaa024-B106">106</xref>), the analytic results reflected the difficulty in sequencing. More specifically, <italic>MUC6</italic> exon 31 produced low mapping quality scores and a commensurate high percentage of SNV calls that failed to pass bioinformatics pipeline quality control filters. For chromosome 11 overall, 89% of SNV calls passed Baylor University (BAYLOR) and Broad Institute (BROAD) filters as defined previously (<xref ref-type="bibr" rid="nlaa024-B1">1</xref>), and only 11% failed to pass one or other filter. In sharp contrast, within <italic>MUC6</italic> exon 31, almost two-thirds of SNVs failed both filters (<xref ref-type="fig" rid="nlaa024-F6">Fig. 6A</xref>). Correspondingly, many sequencing reads that were aligned to <italic>MUC6</italic> exon 31 had low mapping quality (<xref ref-type="fig" rid="nlaa024-F6">Fig. 6B</xref>). These data help explain why the <italic>MUC6</italic> VNTR region was largely excluded from many prior studies.</p>
<fig id="nlaa024-F6" orientation="portrait" position="float">
<label>FIGURE 6.</label>
<caption>
<p>The <italic>MUC6</italic> VNTR is a region with poor mapping quality in high-throughput Alzheimer’s Disease Sequencing Project (ADSP) whole-exome sequencing (WES) data, resulting in undependable sequencing results. Shown are the percentage of single nucleotide variants (SNVs) that passed quality control (QC) filters in Baylor University (BAYLOR) and Broad Institute (BROAD) analyses <bold>(A)</bold> and mapping quality (MAPQ) score in the <italic>AP2A2</italic>/<italic>MUC6</italic> genomic region <bold>(B)</bold>. The percentages were calculated from variant level-filtering results for the BROAD and BAYLOR pipelines contained in consensus VCF file of ADSP WES data <bold>(A)</bold>. The MAPQ scores were obtained from exome alignment BAM file for subject ID = NA06984 (Utah Residents with Northern and Western European Ancestry) in 1000 Genomes Project Phase 3 <bold>(B)</bold>. Note the poor <italic>MUC6</italic> MAPQ scores in the Exon 31 region. This figure was adapted from Katsumata et al (<xref ref-type="bibr" rid="nlaa024-B1">1</xref>), with permission.</p>
</caption>
<graphic xlink:href="nlaa024f6"></graphic>
</fig>
<p>Among other notable features of the mucin genes is their reported potential to vary, within individuals over time, and between human populations. (It is a challenge to determine whether the detected variability signals were due partly to sequencing mistakes.) For example, mucin genes including <italic>MUC6</italic> were on a short list of genes reported to accumulate exomic mutations within individuals during aging (<xref ref-type="bibr" rid="nlaa024-B107">107</xref>). In a mucin gene (<italic>MUC2</italic>) that is near <italic>MUC6</italic> on chromosome 11p15.5, the PTS-encoding repeat sequences differed markedly between “healthy Caucasians” and “healthy Asians” (<xref ref-type="bibr" rid="nlaa024-B108">108</xref>). Systematic comparisons among diverse groups have not been reported for <italic>MUC6</italic>, although a high degree of <italic>MUC6</italic> VNTR polymorphism has been demonstrated within different populations (<xref ref-type="bibr" rid="nlaa024-B19">19</xref>, <xref ref-type="bibr" rid="nlaa024-B99">99</xref>, <xref ref-type="bibr" rid="nlaa024-B109">109</xref>). Variation between diverse populations is a relevant concern because prior studies found that the impacts of specific late-onset AD-risk alleles can vary according to ethnoracial factors (<xref ref-type="bibr" rid="nlaa024-B110">110–114</xref>). However, there are abundant scientific and historical reasons to be cautious with research at the nexus of genetics and race, including in dementia research (<xref ref-type="bibr" rid="nlaa024-B115">115</xref>).</p>
</sec>
<sec>
<title>The Missing/Hidden Heritability Problem in AD Research</title>
<p>A salient question in the field of AD research is: What proportion of risk for developing the AD phenotype is attributable to currently unknown genetic factors? Addressing this involves 2 related questions: (<xref ref-type="bibr" rid="nlaa024-B1">1</xref>) What proportion of AD risk is attributable to genetic factors overall? and (<xref ref-type="bibr" rid="nlaa024-B2">2</xref>) What proportion of AD risk is explained by known genetic risk factors? There is uncertainty about the answers to all of these questions. Multiple levels of complexity are involved, related to the fields of genomics, neuropathology, epidemiology, and large multicenter studies. Prior reviews and meta-analyses have remarked that the disease-related operationalizations (diagnostic criteria and thresholds/cut-points applied) and also the results of prior AD studies “vary greatly” (<xref ref-type="bibr" rid="nlaa024-B116">116</xref>, <xref ref-type="bibr" rid="nlaa024-B117">117</xref>). For all the unanswered questions, there are grounds to hypothesize that a substantial proportion of risk for developing the AD phenotype is due to currently unknown genetic factors—this is the basis for positing a “missing/hidden heritability problem” in AD (<xref ref-type="bibr" rid="nlaa024-B118">118–120</xref>).</p>
<p>As to the degree to which AD is explained by genetic variation, there is not a clear consensus from the literature. In a large Swedish twin study, heritability was estimated to explain 58%–79% of AD cases (<xref ref-type="bibr" rid="nlaa024-B119">119</xref>). Another group reported that genetic differences explained 53% of phenotypic variance of AD (<xref ref-type="bibr" rid="nlaa024-B121">121</xref>). It is also possible that heritability varies across AD subtypes. It was reported that attributable risk due to genetics for episodic memory loss and working memory loss in elderly subjects was approximately 60% and 70%, respectively (<xref ref-type="bibr" rid="nlaa024-B122">122</xref>). A study of dysexecutive AD symptoms estimated the heritability of dysexecutive clinical spectrum symptoms (a quantitative measure) to be 68% (<xref ref-type="bibr" rid="nlaa024-B123">123</xref>). Different approaches have been used to estimate the impact of specific genetic factors on AD neuropathologic subtypes (<xref ref-type="bibr" rid="nlaa024-B124">124</xref>, <xref ref-type="bibr" rid="nlaa024-B125">125</xref>). We emphasize that the heritability of AD is challenging to estimate because data are required from diverse populations (each estimate of heritability may be unique to a particular population, perhaps related to that group’s environment [<xref ref-type="bibr" rid="nlaa024-B126">126</xref>]), with neuropathologic corroboration, and there are many potential confounders.</p>
<p>The known genetic risk factor with the largest impact on public health is the <italic>APOE</italic> ε4 allele. The AD-associated <italic>APOE</italic> ε4 allele is present in approximately one-fourth of persons, with gene frequency varying among different human populations and greatly enriched in many AD study cohorts (<xref ref-type="bibr" rid="nlaa024-B127">127–129</xref>). The <italic>APOE</italic> ε4 allele was initially demonstrated to be associated with the AD phenotype by testing relatively small groups: <italic>APOE</italic> status was compared between 95 AD cases and 139 “unaffected” controls (<xref ref-type="bibr" rid="nlaa024-B130">130</xref>).</p>
<p>Extensive GWAS were performed subsequently. Recent AD GWAS sample sizes were large, and imputation approaches are constantly improving (<xref ref-type="bibr" rid="nlaa024-B64">64</xref>, <xref ref-type="bibr" rid="nlaa024-B73">73</xref>, <xref ref-type="bibr" rid="nlaa024-B131">131</xref>, <xref ref-type="bibr" rid="nlaa024-B132">132</xref>). These advances enabled the identification of dozens of individual non-<italic>APOE</italic> risk alleles, including common variants with subtle effect sizes and rare alleles with larger effects (<xref ref-type="bibr" rid="nlaa024-B60">60</xref>, <xref ref-type="bibr" rid="nlaa024-B64">64</xref>, <xref ref-type="bibr" rid="nlaa024-B73">73</xref>, <xref ref-type="bibr" rid="nlaa024-B133">133–136</xref>). Collectively, and combinatorially, these gene variants may have large impact.</p>
<p>Despite progress in the field, major uncertainties persist. For example, it is not known what proportion of the non-<italic>APOE</italic>-related AD risk is conferred via genetic mechanisms. Determining the scope of this residual genetic risk requires community-based research cohorts because hospital- and clinic-based samples have strong recruitment biases (<xref ref-type="bibr" rid="nlaa024-B137">137–140</xref>). In a high-quality community-based study (Rush University Medical Center cohorts), among n = 1017 autopsied subjects, AD pathology was observed in 62.9%, whereas among the same 1017 individuals, only 25.6% had the <italic>APOE</italic> ε4 allele (<xref ref-type="bibr" rid="nlaa024-B125">125</xref>). In an analysis of data from the population-based Rotterdam Study, the proportion of incident dementia deemed attributable to the <italic>APOE</italic> ε4 allele was estimated to be 20% (<xref ref-type="bibr" rid="nlaa024-B141">141</xref>). These data indicate that a large amount of AD risk is not explained by <italic>APOE</italic>.</p>
<p>Assessing cumulative genetic risk for AD in an individual or a population requires integration of complex genotype data (<xref ref-type="bibr" rid="nlaa024-B64">64</xref>, <xref ref-type="bibr" rid="nlaa024-B131">131</xref>, <xref ref-type="bibr" rid="nlaa024-B132">132</xref>). AD polygenic risk scores (PRS) incorporate information about many gene variants to predict an individual’s risk of expressing the AD phenotype. PRS explained over 80% of AD risk in selected samples (<xref ref-type="bibr" rid="nlaa024-B133">133</xref>, <xref ref-type="bibr" rid="nlaa024-B142">142–147</xref>). Although these studies provided valuable insights into AD genetics, few of these studies had population-representative samples. Some of the prior published papers incorporated data on the variation of thousands of putative risk alleles in the PRS using an unfiltered study design, which may theoretically have included proxies from the <italic>MUC6</italic> region along with many other polymorphisms. Studies that generated a PRS using a predetermined set of well-validated AD-linked SNPs (<xref ref-type="bibr" rid="nlaa024-B148">148–151</xref>) found that predicting AD risk using known risk alleles may be useful in various settings (<xref ref-type="bibr" rid="nlaa024-B152">152</xref>), but these studies also indicated that there are yet-uncharacterized AD risk factors because a substantial proportion of AD risk was not explained by the known gene variants. According to multiple sources, if one assumes that ∼25% of the population harbors the <italic>APOE</italic> ε4 genotype, then the known common risk variants identified by GWAS explained only 30%–50% of total phenotypic variance of late-onset AD (<xref ref-type="bibr" rid="nlaa024-B118">118</xref>, <xref ref-type="bibr" rid="nlaa024-B119">119</xref>, <xref ref-type="bibr" rid="nlaa024-B121">121</xref>, <xref ref-type="bibr" rid="nlaa024-B153">153–158</xref>).</p>
<p>To summarize the current authors’ perspective regarding genetic influence on late-onset AD risk: (<xref ref-type="bibr" rid="nlaa024-B1">1</xref>) It is currently not known how much of AD risk overall is attributable to genetic factors, but it is often estimated that genetic factors are responsible for ∼50%–80% of AD risk and (<xref ref-type="bibr" rid="nlaa024-B2">2</xref>) It also is not known how much of AD risk is attributable to known AD-linked risk alleles, but it may be as low as 30%–50%. With this degree of uncertainty, there are many possibilities, including that there may be currently unknown environmental factors that strongly influence AD risk. Yet as is relevant to the current review article, prior studies also indicate that high-impact AD-associated risk factors may remain to be characterized.</p>
</sec>
<sec>
<title>Where Might the Missing Heritability of AD Be Found?</title>
<p>Although increasing GWAS sample sizes and identifying rare disease-associated alleles are potential strategies for filling in the missing/hidden heritability (<xref ref-type="bibr" rid="nlaa024-B159">159–163</xref>), the challenges go deeper. Surveying the literature provide indications of the need to develop new approaches for genotype/phenotype correlations. Choosing one example from among many: A relatively easily measured human trait is height. Twin studies indicate that height is highly heritable; ∼80% of human height is due to genetic factors (<xref ref-type="bibr" rid="nlaa024-B164">164–166</xref>). A recent large GWAS (n = 253 288 included individuals) identified 697 gene variants associated with human height at genome-wide statistical significance (<xref ref-type="bibr" rid="nlaa024-B167">167</xref>). These data increased the explanation of the genetic influences on human height from prior studies (<xref ref-type="bibr" rid="nlaa024-B168">168</xref>), yet, collectively, these 697 gene variants still explained only one-fifth of the phenotypic (height) variance in the sample (<xref ref-type="bibr" rid="nlaa024-B167">167</xref>). Even taking into account “all common variants” only “captured 60% of heritability” (<xref ref-type="bibr" rid="nlaa024-B167">167</xref>). Thus, despite large sample sizes and improving imputation methods, some phenotypes may not be fully explained by readily characterized small genetic variants.</p>
<p>One reason for the persistent knowledge gaps is that much of the human genome has remained practically off-limits to existing high-throughput genome-wide sequencing analyses. Related challenges include coping with large structural variants, genomic regions with substantial interindividual variation, and incomplete annotation of the human genome. Further, genomic regions with repetitive sequences were trimmed off by the bioinformatics pipelines used to identify variants in both GWAS and “next-generation sequencing” (NGS) data (<xref ref-type="bibr" rid="nlaa024-B169">169–171</xref>).</p>
<p>A recent, directly relevant study by Ebbert et al analyzed ADSP NGS data systematically and reported that there are “many regions with few mappable reads that we call dark by depth, and others that have ambiguous alignment, called camouflaged. … The number of genes affected by dark and camouflaged regions was surprisingly high. We identified 36 794 total dark regions across 6054 gene bodies, 3804 of which were protein coding genes…” (<xref ref-type="bibr" rid="nlaa024-B171">171</xref>).</p>
<p>The discovery of extremely widespread “dark or camouflaged” regions in human genomes has profound implications. This may be particularly true for studies that correlate NGS data with neurologic disease endophenotypes. Even if one hypothesized that genomic regions which can be reliably sequenced are more likely to be disease-driving than the many regions that confound current sequencing technologies, it would still be quite credible that the extensive “dark or camouflaged” regions contain genetic variants which influence human phenotypes. However, for dozens of different human neurologic diseases, a specific tandem repeat-rich genomic region was the established cause of the disease phenotype (<xref ref-type="bibr" rid="nlaa024-B172">172–174</xref>). This tendency makes it all the more likely that the missing/hidden heritability for AD could be partly explained by analyzing the widespread, and hitherto poorly characterized, repeat-rich segments of the human genome (<xref ref-type="bibr" rid="nlaa024-B83">83</xref>).</p>
</sec>
<sec>
<title>The <italic>MUC6/AP2A2</italic> Locus and the AD Endophenotype: Data and Cautionary Considerations</title>
<p>The <italic>MUC6</italic> locus was initially identified to contain a candidate AD-associated polymorphism through analyses of ADSP WES data (n = 5142 AD cases and 4889 control subjects of European ancestry were included) (<xref ref-type="bibr" rid="nlaa024-B1">1</xref>). We employed an optimal sequence kernel association test (SKAT-O) (<xref ref-type="bibr" rid="nlaa024-B175">175</xref>) to survey genes for SNVs associated with the AD phenotype (<xref ref-type="bibr" rid="nlaa024-B1">1</xref>). The results of that gene-based analysis are shown in <xref ref-type="fig" rid="nlaa024-F7">Figure 7</xref>, using data charted in “Manhattan plot” format. Several aspects of these findings can be appreciated: 1&gt; The reported association between <italic>MUC6</italic> gene variation and the AD phenotype was strong (p &lt; 10<sup>−25</sup>); 2&gt; The other genes associated significantly with the AD phenotype in this analysis agreed with prior published studies (<italic>TREM2</italic> [<xref ref-type="bibr" rid="nlaa024-B176">176</xref>, <xref ref-type="bibr" rid="nlaa024-B177">177</xref>] on chromosome 6 and <italic>BCAM</italic> [<xref ref-type="bibr" rid="nlaa024-B178">178</xref>], which is located near <italic>APOE</italic> on chromosome 19); and, 3&gt; There was not a haphazard pattern of nominally positive “hits” that would indicate a systematic tendency toward spurious false-positivity.</p>
<fig id="nlaa024-F7" orientation="portrait" position="float">
<label>FIGURE 7.</label>
<caption>
<p>Manhattan plot of gene-based analysis of Alzheimer’s Disease Sequencing Project (ADSP) whole-exome sequencing (WES) data, showing association with Alzheimer’s disease phenotype in that data set. Optimal-unified sequence kernel association test (SKAT-O) association results are depicted for n = 10 031 (5142 AD cases and 4889 controls) subjects. The gene with lowest p value in this genome-wide scan was mucin 6 (<italic>MUC6</italic>), with p = 1.38 × 10<sup>−26</sup>, and the second lowest p value was triggering receptor expressed on myeloid cells 2 (<italic>TREM2</italic>). Relatively rare alleles in both <italic>TREM2</italic> and basal cell adhesion molecule (<italic>BCAM</italic>), which is located near <italic>APOE</italic> on chromosome 19, were both previously associated with the AD phenotype (<xref ref-type="bibr" rid="nlaa024-B106">106</xref>, <xref ref-type="bibr" rid="nlaa024-B176">176</xref>, <xref ref-type="bibr" rid="nlaa024-B178">178</xref>). This figure was adapted from Katsumata et al (<xref ref-type="bibr" rid="nlaa024-B1">1</xref>), with permission.</p>
</caption>
<graphic xlink:href="nlaa024f7"></graphic>
</fig>
<p>With regard to the hypothesis that <italic>MUC6</italic> contains an AD-associated polymorphism, there were reasons to be skeptical. Each of the <italic>MUC6</italic> SNVs that was initially found to be associated with the AD phenotype was located within the same unique, poorly annotated, and highly polymorphic VNTR region (<xref ref-type="bibr" rid="nlaa024-B1">1</xref>). It was previously demonstrated that the <italic>MUC6</italic> VNTR region is prone to producing false-positive results in WES data because of the extremely high local polymorphism (<xref ref-type="bibr" rid="nlaa024-B109">109</xref>, <xref ref-type="bibr" rid="nlaa024-B179">179</xref>). One group suggested that <italic>MUC6</italic> belongs on a “blacklist” of genes that should be viewed with extraordinary skepticism when predicting pathogenicity based on WES results, because of this “excess heterogeneity” (<xref ref-type="bibr" rid="nlaa024-B180">180</xref>). The very low nominal p value for the <italic>MUC6</italic>/AD association (<xref ref-type="fig" rid="nlaa024-F7">Fig. 7</xref>) could be interpreted as another indicator that technical bias influenced the results. As stated above, it is possible that the <italic>MUC6</italic> polymorphism could be variable between populations of different ancestry. This needs to be evaluated carefully, because population structure could also introduce false-positive associations. A consideration of these factors makes it seem like a credible hypothesis that <italic>MUC6</italic> genotype/phenotype associations reported by outside authors (e.g., the association between a <italic>MUC6</italic> VNTR gene variant and brain herpesvirus infection [30]) could be false-positives.</p>
<p>Despite these warning signals, we assert that <italic>MUC6</italic> should not be universally or compulsorily ignored. Merely because a gene contains many sequence elements that are highly variable in a population does not mean that all of those genetic variants are equally benign. As specific examples, other genes that are hypothesized to be pathogenetic (e.g., <italic>HLA-DRB1</italic> in multiple sclerosis and AD [<xref ref-type="bibr" rid="nlaa024-B181">181–184</xref>] and <italic>FIG4</italic> in amyotrophic lateral sclerosis [<xref ref-type="bibr" rid="nlaa024-B185">185–187</xref>]), also were “blacklisted” for extreme heterozygosity, as <italic>MUC6</italic> was (<xref ref-type="bibr" rid="nlaa024-B180">180</xref>). It may be argued that <italic>MUC6</italic> deserves added attention because the gene contains a highly polymorphic VNTR region, which has been credibly linked to human diseases (see above). Moreover, thousands of published WES studies did not produce a signal at the <italic>MUC6</italic> locus. The prior literature does, however, indicate that an abundance of caution is merited when studying the association between <italic>MUC6</italic> polymorphism and human disease.</p>
<p>Concerns have also been raised about potential sources of systematic bias in the ADSP WES data set that we used to identify the <italic>MUC6</italic> genotype/AD phenotype association. The <italic>MUC6</italic> SNV calls were derived using bioinformatics pipelines affected by many potential confounders (<xref ref-type="bibr" rid="nlaa024-B106">106</xref>, <xref ref-type="bibr" rid="nlaa024-B188">188</xref>). In 2016, the National Institute on Aging Genetics of Alzheimer’s Disease Data Storage Site (NIAGADS) posted a topical document titled “Review and Proposed Actions for False-Positive Association Results in ADSP Case-Control Data”; the entire document can be read online (<xref ref-type="bibr" rid="nlaa024-B189">189</xref>). Although not mentioning <italic>MUC6</italic> specifically, this posting did refer to the ADSP WES data set version that we had analyzed (phs000572.v6.p4), and stated that “differential effects between cases and controls [led] to strong but spurious associations”. Among the notes of caution were: “Different capture protocols were used at the different sequencing centers, and these … could result in biases.” And: “Association analysis of case-control genotypes with AD with covariate adjustment for time period of sample sequence processing at the Broad Institute appeared to eliminate most potentially spurious associations.” This analysis was complemented by “Sanger sequencing … . to validate heterozygous calls” (<xref ref-type="bibr" rid="nlaa024-B189">189</xref>). (The reported Sanger sequencing experiments focused on SNV calls but not on tandem repeat expansion.) Ensuing published work that evaluated AD-linked rare variants in the ADSP WES data set did not mention <italic>MUC6</italic> (<xref ref-type="bibr" rid="nlaa024-B171">171</xref>, <xref ref-type="bibr" rid="nlaa024-B176">176–178</xref>).</p>
<p>Consistent with the NIAGADS cautionary posting, we reported experimental evidence that some of the individual <italic>MUC6</italic> SNV calls that had initially focused our interest in the <italic>MUC6</italic> VNTR region were not correct (<xref ref-type="bibr" rid="nlaa024-B1">1</xref>). For a small sample of cases, we generated SNV calls via a direct polymerase chain reaction (PCR)-based assay, and the results were different from the SNV calls for the same cases according to the initial ADSP data (<xref ref-type="bibr" rid="nlaa024-B1">1</xref>). Based on these findings, if there was a true positive signal of pathogenicity at the <italic>MUC6</italic> locus, it likely was not a scenario where individual disease-causing gene variants were identified.</p>
<p>We conclude that the phenomenon of the <italic>MUC6</italic> gene variants’ status being associated with the AD phenotype (<xref ref-type="fig" rid="nlaa024-F7">Fig. 7</xref>) may have been influenced by many factors. As described above, there are reasons to be skeptical: The <italic>MUC6</italic> region’s extreme heterozygosity raises the likelihood of a false-positive signal; specific SNV calls in the early ADSP data set were incorrect; and, the initial ADSP analyses were systematically biased. However, the full impact of that bias was not determined, and we underscore the critical distinction between the SNVs which were shown to be problematic and/or mis-called, versus the tandem repeat expansion of <italic>MUC6</italic> that was not addressed by any other workers in the dementia field. The known data are compatible with a testable hypothesis: There was a meaningful underlying biological association between the number of <italic>MUC6</italic> tandem repeats and the AD phenotype. Put another way, the early analyses of WES data may have provided a proxy flag, signaling that <italic>MUC6</italic> tandem repeat expansion is associated with AD risk.</p>
</sec>
<sec>
<title>Additional Studies, Preliminary Assessment of Public Health Impact, and Knowledge Gaps</title>
<p>Following the results of ADSP WES data analyses, we used experimental tools tailored specifically for studying the <italic>MUC6</italic> VNTR region: The focus was on the association between AD pathology and <italic>MUC6</italic> tandem repeat expansion, rather than on SNV-type genetic variation. The study sample was the UK-ADC autopsy cohort (<xref ref-type="bibr" rid="nlaa024-B190">190</xref>) as described in detail (<xref ref-type="bibr" rid="nlaa024-B1">1</xref>). Consistent with prior studies (<xref ref-type="bibr" rid="nlaa024-B19">19</xref>, <xref ref-type="bibr" rid="nlaa024-B98">98</xref>), analyzing the autopsied subjects’ genomic DNA with PCR revealed a wide range of <italic>MUC6</italic> VNTR sizes. In a Discovery subsample (n = 119) of autopsied subjects, the size of the <italic>MUC6</italic> VNTR region was associated with the severity of phospho-tau pathology in neocortical brain regions (<xref ref-type="fig" rid="nlaa024-F8">Fig. 8</xref>). For the risk allele, we used as a threshold criterion the largest 33%ile <italic>MUC6</italic> VNTR region size (top tertile) as measured by PCR, because this was the cut-point in the Discovery cohort with the strongest association between the <italic>MUC6</italic> VNTR region size and phospho-tau pathologic severity (<xref ref-type="bibr" rid="nlaa024-B1">1</xref>). That main finding was reproduced in a separate Replication cohort (n = 173).</p>
<fig id="nlaa024-F8" orientation="portrait" position="float">
<label>FIGURE 8.</label>
<caption>
<p>Experiments were performed to test the association(s) between Alzheimer’s disease phospho-Tau (pTau) pathology, detected with immunohistochemistry <bold>(A–C)</bold>, and the size of the <italic>MUC6</italic> VNTR as measured using a PCR-based assay <bold>(D)</bold>. Digital quantification of pTau pathologic burden was used for correlation with the size of the <italic>MUC6</italic> VNTR polymorphism. Panels <bold>(A–C)</bold> show representative results of pTau immunohistochemistry (IHC) from the temporal neocortex (Brodmann areas 21/22) of a subject with dementia. The actual pTau immunostain is shown in panel <bold>(A)</bold>, and at higher magnification in panel <bold>(B)</bold>. The false-colored data <bold>(C)</bold> conveys the quantified pTau pathology (dark red). Parameters from different brain regions were analyzed to compare the amount of pTau pathology in subjects stratified by the size of the largest detected <italic>MUC6</italic> VNTR region according to PCR <bold>(D)</bold>. PCR results are shown for 5 representative cases; those with one amplicon band on the gel are hypothesized to be homozygous, 2 bands indicate a heterozygote. The slower running (higher on the gel) samples represent the larger alleles. Results are summarized <bold>(E)</bold>. The reason we compared pTau pathology in temporal neocortex in the Replication cohort cases with the largest 33%ile amplicons as measured by PCR (top tertile), to the remaining two-thirds of cases, is that this is the region and threshold in the Discovery cohort with the strongest association between the <italic>MUC6</italic> VNTR region size and pTau pathology (<xref ref-type="bibr" rid="nlaa024-B1">1</xref>). This figure was adapted from Katsumata et al (<xref ref-type="bibr" rid="nlaa024-B1">1</xref>), with permission.</p>
</caption>
<graphic xlink:href="nlaa024f8"></graphic>
</fig>
<p>None of our prior published analyses combined the abovementioned Discovery and Replication cohorts from the UK-ADC data set. We here show results of analyses factoring in all of these subjects together. The criterion for operationalizing the <italic>MUC6</italic> risk allele was again that the size of the VNTR region was in the top tertile in that cohort according to the PCR assay. The summary data were analyzed to compare parameters related to AD neuropathologic changes using conventional stage-based AD pathology severity metrics.</p>
<p>
<xref ref-type="table" rid="nlaa024-T3">Tables 3</xref> and <xref ref-type="table" rid="nlaa024-T4">4</xref> show the results for comparisons of AD neuropathology in the UK-ADC combined cohort, stratifying by <italic>APOE</italic> ε4 allele status and <italic>MUC6</italic> VNTR allele status. <xref ref-type="table" rid="nlaa024-T3">Table 3</xref> shows how the <italic>MUC6</italic> VNTR and <italic>APOE</italic> ε4 allele genotypes were correlated with the number of individuals in specific Braak NFT stage (<xref ref-type="bibr" rid="nlaa024-B191">191</xref>) groups. There were a total of n = 101 cases with Braak NFT stage VI (which indicates the most severe AD pathology) in this analysis. The assessment of <italic>MUC6</italic> VNTR risk allele status reduced the number of severe AD cases unexplained by a risk allele—the number of <italic>MUC6</italic>−/<italic>APOE</italic>− cases with Braak NFT stage VI was only n = 15. A test using analysis of deviance for a logistic regression model of Braak NFT stage VI, regressed on <italic>MUC6</italic> VNTR status, <italic>APOE</italic> ε4 presence, and their interaction, exhibits high statistical significance (LRT-p = 1.08 × 10<sup>−7</sup>). A reciprocal tendency for enrichment of <italic>MUC6</italic>−/<italic>APOE</italic>− cases can be observed among subjects with relatively low neurofibrillary pathology, Braak NFT stages 0–III. <xref ref-type="table" rid="nlaa024-T4">Table 4</xref> shows the results for neuritic amyloid plaques, graded according to the Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) neuritic plaque density scores (<xref ref-type="bibr" rid="nlaa024-B192">192</xref>). Among the subjects who lacked the <italic>APOE</italic> ε4 allele, carrying the <italic>MUC6</italic> VNTR risk allele correlated with having highest grade density of neuritic amyloid plaques. The same general trend was present among those with the <italic>APOE</italic> ε4 allele. This is the first demonstration of amyloid plaque-associated pathology correlated with the <italic>MUC6</italic> VNTR genotype.</p>
<table-wrap id="nlaa024-T3" orientation="portrait" position="float">
<label>TABLE 3.</label>
<caption>
<p>Braak Neurofibrillary Tangle (NFT) Stage Groups in the UK-ADC Autopsy Cohort (<xref ref-type="bibr" rid="nlaa024-B1">1</xref>) (n = 292<xref ref-type="table-fn" rid="tblfn5">*</xref>), Stratifying by <italic>APOE</italic> ε4 Status (<italic>APOE4+/</italic>−<italic>)</italic> and by Whether or Not the <italic>MUC6</italic> VNTR Region Is in the Top Size Tertile (<italic>MUC6+/</italic>−)</p>
</caption>
<table frame="hsides" rules="groups">
<colgroup span="1">
<col align="left" span="1" valign="top"/>
<col align="center" span="1" valign="top"/>
<col align="center" span="1" valign="top"/>
<col align="char" char="." span="1" valign="top"/>
<col align="char" char="." span="1" valign="top"/>
</colgroup>
<thead>
<tr>
<th colspan="1" rowspan="1">Allele Status<xref ref-type="table-fn" rid="tblfn6"><sup>†</sup></xref></th>
<th colspan="1" rowspan="1">Total n, Each Group</th>
<th colspan="1" rowspan="1">n, Braak NFT Stage VI Cases</th>
<th colspan="1" rowspan="1">% Braak NFT Stage VI Cases</th>
<th colspan="1" rowspan="1">% Braak NFT Stages 0–III Cases</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="1" rowspan="1">
<italic>APOE4−/MUC6−</italic>
</td>
<td colspan="1" rowspan="1">n=104</td>
<td colspan="1" rowspan="1">n=15</td>
<td colspan="1" rowspan="1">14.4</td>
<td colspan="1" rowspan="1">55.8</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
<italic>APOE4−/MUC6+</italic>
</td>
<td colspan="1" rowspan="1">n=51</td>
<td colspan="1" rowspan="1">n=22</td>
<td colspan="1" rowspan="1">43.1</td>
<td colspan="1" rowspan="1">31.4</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
<italic>APOE4+/MUC6−</italic>
</td>
<td colspan="1" rowspan="1">n=71</td>
<td colspan="1" rowspan="1">n=32</td>
<td colspan="1" rowspan="1">45.1</td>
<td colspan="1" rowspan="1">23.9</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
<italic>APOE4+/MUC6+</italic>
</td>
<td colspan="1" rowspan="1">n=60</td>
<td colspan="1" rowspan="1">n=32</td>
<td colspan="1" rowspan="1">53.3</td>
<td colspan="1" rowspan="1">16.7</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="tblfn5">
<label>*</label>
<p>n = 6 had missing Braak NFT stage.</p>
</fn>
<fn id="tblfn6">
<label></label>
<p>
<sup>†</sup>“+” indicates presence of at least 1 putative risk allele.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="nlaa024-T4" orientation="portrait" position="float">
<label>TABLE 4.</label>
<caption>
<p>Association Between CERAD Neuritic Amyloid Plaque Density Scores and PCR-Measured <italic>MUC6</italic> VNTR Region Size Stratified by <italic>APOE</italic> ε4 Allele Status in the UK-ADC Cohort (<xref ref-type="bibr" rid="nlaa024-B1">1</xref>); n = 292</p>
</caption>
<table frame="hsides" rules="groups">
<colgroup span="1">
<col align="left" span="1" valign="top"/>
<col align="center" span="1" valign="top"/>
<col align="center" span="1" valign="top"/>
<col align="center" span="1" valign="top"/>
</colgroup>
<thead>
<tr>
<th colspan="1" rowspan="2"></th>
<th colspan="2" rowspan="1">Numbers of Subjects by Category<hr/></th>
<th colspan="1" rowspan="2">p Value<xref ref-type="table-fn" rid="tblfn7">*</xref></th>
</tr>
<tr>
<th colspan="1" rowspan="1">Bottom 2 Tertiles VNTR Size</th>
<th colspan="1" rowspan="1">Top Tertile VNTR Size</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="1" rowspan="1">
<italic>APOE</italic> ε4 (−): n = 159</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> CERAD none, possible, or probable</td>
<td colspan="1" rowspan="1">n = 72</td>
<td colspan="1" rowspan="1">n = 22</td>
<td colspan="1" rowspan="2">0.0025</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> CERAD definite (NP density highest)</td>
<td colspan="1" rowspan="1">n = 34</td>
<td colspan="1" rowspan="1">n = 31</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
<italic>APOE</italic> ε4 (+): n = 133</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> CERAD none, possible, or probable</td>
<td colspan="1" rowspan="1">n = 26</td>
<td colspan="1" rowspan="1">n = 13</td>
<td colspan="1" rowspan="2">0.12</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> CERAD definite (NP density highest)</td>
<td colspan="1" rowspan="1">n = 47</td>
<td colspan="1" rowspan="1">n = 47</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="tblfn7">
<label>*</label>
<p>Chi-squared test result, two-tailed test.</p>
</fn>
<fn id="tblfn8">
<p>CERAD, Consortium to Establish a Registry for Alzheimer’s Disease (<xref ref-type="bibr" rid="nlaa024-B192">192</xref>).</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Published data (<xref ref-type="bibr" rid="nlaa024-B1">1</xref>) and a literature review provide support for hypotheses that link the <italic>MUC6</italic> VNTR region polymorphism with AD pathogenesis (<xref ref-type="fig" rid="nlaa024-F9">Fig. 9</xref>). The expanded version of the <italic>MUC6</italic> VNTR region was associated with decreased <italic>AP2A2</italic> expression (<xref ref-type="bibr" rid="nlaa024-B1">1</xref>). <italic>MUC6</italic> VNTR polymorphism thus may affect CCV function, which is related to autophagy and functions in processing neurodegenerative disease-associated proteins such as APP and Tau (<xref ref-type="bibr" rid="nlaa024-B41">41</xref>, <xref ref-type="bibr" rid="nlaa024-B42">42</xref>, <xref ref-type="bibr" rid="nlaa024-B75">75</xref>). Alternatively, or in parallel, the combination of impacts on <italic>MUC6</italic> and <italic>AP2A2</italic> could influence the gut microbiome and/or viral immunity, therefore affecting pathogenetic cascades relevant to AD. The long-term effects of the variation of the <italic>MUC6</italic> VNTR region may cause or accentuate pathologies, including tau neurofibrillary degeneration and neuritic amyloid plaques, in aged persons’ brains.</p>
<fig id="nlaa024-F9" orientation="portrait" position="float">
<label>FIGURE 9.</label>
<caption>
<p>Hypotheses related to pathogenetic mechanisms: a variable number of tandem repeat (VNTR) region within the <italic>MUC6</italic> gene on Chr. 11p constitutes a common driver of the Alzheimer’s disease (AD) phenotype. The large-sized VNTR (i.e., the risk allele, which is ∼30% prevalent in our preliminary studies) is associated with the severity of AD-type pathology, particularly tau neurofibrillary pathology. The <italic>MUC6</italic> VNTR region is immediately downstream of the <italic>AP2A2</italic> gene. The AP2A2 gene product is an “adaptor” protein involved in clathrin-coated vesicle (CCV) formation at the plasma membrane (<xref ref-type="bibr" rid="nlaa024-B33">33</xref>, <xref ref-type="bibr" rid="nlaa024-B35">35</xref>, <xref ref-type="bibr" rid="nlaa024-B38">38</xref>). We found that <italic>AP2A2</italic> expression is dysregulated in persons with the large-sized VNTR region (<xref ref-type="bibr" rid="nlaa024-B1">1</xref>). There are also lines of evidence connecting <italic>MUC6</italic> with the gut microbiome and viral immunity as discussed in the text of the present review; these inflammatory influences may contribute to altered risk of AD.</p>
</caption>
<graphic xlink:href="nlaa024f9"></graphic>
</fig>
<p>It is premature to make generalizations about the influence of the <italic>MUC6</italic> VNTR expansion on public health. For now, we can only analyze the relatively small UK-ADC autopsy cohort sample. We performed preliminary calculations of the AD odds ratio (OR), using the combined sample from the UK-ADC autopsy cohort (n = 292); see <xref ref-type="fig" rid="nlaa024-F10">Figure 10</xref>. The <italic>MUC6</italic> VNTR risk allele is ∼35% prevalent (top tertile) in this cohort, and the <italic>MUC6</italic> VNTR risk allele OR for AD is 2.10 (95% CI 1.07–4.18) using the severity of temporal neocortex NFT pathology as the endophenotype, compared to <italic>APOE</italic> ε4 OR = 2.87 (95% CI 1.55–5.58) for the same endophenotype and in the same cohort.</p>
<fig id="nlaa024-F10" orientation="portrait" position="float">
<label>FIGURE 10.</label>
<caption>
<p>Preliminary estimations of public health impact of the <italic>MUC6</italic> VNTR polymorphism: risk allele prevalence and Alzheimer’s disease (AD) “odds ratio” (OR). According to our preliminary data in the University of Kentucky AD Center cohort, the AD OR for the top-tertile risk allele is 2.10 (95% CI 1.07–4.18) using Tau pathology in the temporal neocortex (Brodmann areas 21/22) as the endophenotype, compared to <italic>APOE</italic> ε4 OR = 2.87 (95% CI 1.55–5.58). In prior work, other non-<italic>APOE</italic> common late-onset AD-risk alleles’ OR were &lt;1.5 (60). The UK-ADC cohort is a relatively small sample that lacks socioeconomic or ethnoracial diversity. Additional studies are required to better understand the public health impact of the <italic>MUC6</italic> VNTR polymorphism.</p>
</caption>
<graphic xlink:href="nlaa024f10"></graphic>
</fig>
<p>Among tested subjects in the UK-ADC sample, persons with the <italic>APOE</italic> ε4 allele were relatively likely to also have the <italic>MUC6</italic> VNTR risk allele (<xref ref-type="table" rid="nlaa024-T3">Table 3</xref>): 32.8% of <italic>APOE</italic> ε4(−) subjects had the <italic>MUC6</italic> VNTR risk allele, whereas 45.8% of the <italic>APOE</italic> ε4(+) subjects had the <italic>MUC6</italic> VNTR risk allele. Although this was only a marginal trend (p &lt; 0.03) in this small cohort, this phenomenon is notable. Primarily, to evaluate the impact of the <italic>MUC6</italic> VNTR risk allele appropriately, we factored each subject’s <italic>APOE</italic> ε4 allele status into our analytic model (<xref ref-type="bibr" rid="nlaa024-B1">1</xref>), so as not to overestimate the associative impact of the <italic>MUC6</italic> VNTR risk allele.</p>
<p>The UK-ADC sample’s enrichment of subjects with both the <italic>MUC6</italic> VNTR risk allele and (in the same persons) the <italic>APOE</italic> ε4 allele may have other implications. As noted previously, AD-related study samples are often influenced by recruitment bias to include a disproportionately high number of individuals at genetic risk for AD-type dementia. (The allele frequency for the <italic>APOE</italic> ε4 allele was &gt;45% in this dementia-enriched UK-ADC convenience sample, although the population frequency is ∼25%.) If the <italic>MUC6</italic> VNTR risk allele was indeed influencing AD risk, one would hypothesize that there should be a corresponding tendency to recruit high-risk subjects with both the large <italic>MUC6</italic> VNTR and the <italic>APOE</italic> ε4 allele; this bias may not be restricted to the UK-ADC cohort. If this were true, then, an additional hypothesis would follow: Just as an estimate of the impact of the <italic>MUC6</italic> VNTR must be adjusted to account for the presence of the <italic>APOE</italic> ε4 allele in carriers of both risk alleles, so should an estimate of the impact of the <italic>APOE</italic> ε4 allele be adjusted to correct for the presence of the <italic>MUC6</italic> VNTR risk allele. In other words, a portion of AD risk which hitherto has been attributed to <italic>APOE</italic>, may actually have been due to the <italic>MUC6</italic> VNTR allele, because dementia research study subjects may tend to harbor both risk alleles simultaneously due to recruitment bias. Further, persons with the <italic>APOE</italic> ε4 allele but with a risk mitigating (short) <italic>MUC6</italic> VNTR allele may theoretically be less likely to be represented in dementia research cohorts.</p>
<p>Although the data gathered related to the <italic>MUC6</italic> VNTR and AD risk are suggestive so far, there are also reasons to be cautious, in addition to those mentioned above. The sample that we assessed was relatively small by genomics study standards. These findings require further corroboration. The UK-ADC autopsy cohort is a relatively homogenous demographic sample, so there is a need for assessment of more diverse and population-representative cohorts. There are other key knowledge gaps that may help guide future studies. For example, we do not know the actual <italic>MUC6</italic> VNTR sequences for any of the cases we have analyzed. To characterize the <italic>MUC6</italic> VNTR polymorphism, a PCR-based assay was developed which indicated the approximate size of the <italic>MUC6</italic> VNTR (<xref ref-type="fig" rid="nlaa024-F8">Fig. 8D</xref>), because we lacked access to a quantitative tandem repeat assay such as is available for <italic>C9ORF72</italic> repeat number characterization (<xref ref-type="bibr" rid="nlaa024-B193">193</xref>, <xref ref-type="bibr" rid="nlaa024-B194">194</xref>). An improved <italic>MUC6</italic> VNTR assay or sequencing platform is required for both research and possible future clinical purposes. At this locus and others, there remains much to be learned about the “dark and camouflaged” (<xref ref-type="bibr" rid="nlaa024-B171">171</xref>) regions of the human genome.</p>
</sec>
</sec>
<sec sec-type="supplementary-material">
<title>Supplementary Material</title>
<supplementary-material content-type="local-data" id="sup1">
<label>nlaa024_Supplementary_Data</label>
<media xlink:href="nlaa024_supplementary_data.docx">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
</sec>
</body>
<back>
<sec>
<title></title>
<p>Funding included grants P30 AG028383, R01 AG057187, R01 AG042475, R56 AG057191, and U01 AG016976 from the National Institute on Aging/National Institutes of Health (NIH). The Genotype-Tissue Expression (GTEx) project was supported by the Common Fund of the Office of the Director of the NIH, and by NCI, NHGRI, NHLBI, NIDA, NIMH, and NINDS. We are deeply grateful to all of the study participants, clinical workers, and researchers who helped make this article possible. See <xref ref-type="supplementary-material" rid="sup1">Supplementary Data</xref> for additional acknowledgments.</p>
<p>The authors have no duality or conflicts of interest to declare.</p>
</sec>
<ref-list id="ref1">
<title>REFERENCES</title>
<ref id="nlaa024-B1">
<label>1</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Katsumata</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Fardo</surname><given-names>DW</given-names></name>, <name name-style="western"><surname>Bachstetter</surname><given-names>AD</given-names></name></person-group>, <etal>et al</etal>
<article-title>Alzheimer disease pathology-associated polymorphism in a complex variable number of tandem repeat region within the MUC6 gene, near the AP2A2 gene</article-title>. <source/>J Neuropathol Exp Neurol<year>2019</year>;<volume>79</volume>:<fpage>3</fpage>–<lpage>21</lpage></mixed-citation>
</ref>
<ref id="nlaa024-B2">
<label>2</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Ambrosini</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Paul</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal>
<article-title>Human subtelomeric duplicon structure and organization</article-title>. <source/>Genome Biol<year>2007</year>;<volume>8</volume>:<fpage>R151</fpage><pub-id pub-id-type="pmid">17663781</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B3">
<label>3</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Rousseau</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Byrne</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Griesinger</surname><given-names>G</given-names></name></person-group>, <etal>et al</etal>
<article-title>Allelic association and recombination hotspots in the mucin gene (MUC) complex on chromosome 11p15.5</article-title>. <source/>Ann Human Genet<year>2007</year>;<volume>71</volume>:<fpage>561</fpage>–<lpage>9</lpage><pub-id pub-id-type="pmid">17535267</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B4">
<label>4</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Corfield</surname><given-names>AP.</given-names></name></person-group>
<article-title>Mucins: A biologically relevant glycan barrier in mucosal protection</article-title>. <source/>Biochim Biophys Acta<year>2015</year>;<volume>1850</volume>:<fpage>236</fpage>–<lpage>52</lpage><pub-id pub-id-type="pmid">24821013</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B5">
<label>5</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Ho</surname><given-names>SB</given-names></name>, <name name-style="western"><surname>Roberton</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Shekels</surname><given-names>LL</given-names></name></person-group>, <etal>et al</etal>
<article-title>Expression cloning of gastric mucin complementary DNA and localization of mucin gene expression</article-title>. <source/>Gastroenterology<year>1995</year>;<volume>109</volume>:<fpage>735</fpage>–<lpage>47</lpage><pub-id pub-id-type="pmid">7657101</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B6">
<label>6</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Gipson</surname><given-names>IK</given-names></name>, <name name-style="western"><surname>Ho</surname><given-names>SB</given-names></name>, <name name-style="western"><surname>Spurr-Michaud</surname><given-names>SJ</given-names></name></person-group>, <etal>et al</etal>
<article-title>Mucin genes expressed by human female reproductive tract epithelia</article-title>. <source/>Biol Reprod<year>1997</year>;<volume>56</volume>:<fpage>999</fpage>–<lpage>1011</lpage><pub-id pub-id-type="pmid">9096884</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B7">
<label>7</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Seregni</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Botti</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Massaron</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal>
<article-title>Structure, function and gene expression of epithelial mucins</article-title>. <source/>Tumori<year>1997</year>;<volume>83</volume>:<fpage>625</fpage>–<lpage>32</lpage><pub-id pub-id-type="pmid">9267478</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B8">
<label>8</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Bartman</surname><given-names>AE</given-names></name>, <name name-style="western"><surname>Buisine</surname><given-names>MP</given-names></name>, <name name-style="western"><surname>Aubert</surname><given-names>JP</given-names></name></person-group>, <etal>et al</etal>
<article-title>The MUC6 secretory mucin gene is expressed in a wide variety of epithelial tissues</article-title>. <source/>J Pathol<year>1998</year>;<volume>186</volume>:<fpage>398</fpage>–<lpage>405</lpage><pub-id pub-id-type="pmid">10209489</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B9">
<label>9</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Toribara</surname><given-names>NW</given-names></name>, <name name-style="western"><surname>Roberton</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Ho</surname><given-names>SB</given-names></name></person-group>, <etal>et al</etal>
<article-title>Human gastric mucin. Identification of a unique species by expression cloning</article-title>. <source/>J Biol Chem<year>1993</year>;<volume>268</volume>:<fpage>5879</fpage>–<lpage>85</lpage><pub-id pub-id-type="pmid">7680650</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B10">
<label>10</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Moniaux</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Escande</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Porchet</surname><given-names>N</given-names></name></person-group>, <etal>et al</etal>
<article-title>Structural organization and classification of the human mucin genes</article-title>. <source/>Front Biosci<year>2001</year>;<volume>6</volume>:<fpage>D1192</fpage>–<lpage>206</lpage><pub-id pub-id-type="pmid">11578969</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B11">
<label>11</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Van Seuningen</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Pigny</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Perrais</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal>
<article-title>Transcriptional regulation of the 11p15 mucin genes. Towards new biological tools in human therapy, in inflammatory diseases and cancer?</article-title><source/>Front Biosci<year>2001</year>;<volume>6</volume>:<fpage>D1216</fpage>–<lpage>34</lpage><pub-id pub-id-type="pmid">11578973</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B12">
<label>12</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Gosalia</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Leir</surname><given-names>SH</given-names></name>, <name name-style="western"><surname>Harris</surname><given-names>A.</given-names></name></person-group>
<article-title>Coordinate regulation of the gel-forming mucin genes at chromosome 11p15.5</article-title>. <source/>J Biol Chem<year>2013</year>;<volume>288</volume>:<fpage>6717</fpage>–<lpage>25</lpage><pub-id pub-id-type="pmid">23303185</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B13">
<label>13</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Voynow</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Gendler</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Rose</surname><given-names>MC.</given-names></name></person-group>
<article-title>Regulation of mucin genes in chronic inflammatory airway diseases</article-title>. <source/>Am J Respir Cell Mol Biol<year>2006</year>;<volume>34</volume>:<fpage>661</fpage>–<lpage>5</lpage><pub-id pub-id-type="pmid">16456183</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B14">
<label>14</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Niv</surname><given-names>Y.</given-names></name></person-group>
<article-title>
<italic>Helicobacter pylori</italic> and gastric mucin expression: A systematic review and meta-analysis</article-title>. <source/>World J Gastroenterol<year>2015</year>;<volume>21</volume>:<fpage>9430</fpage>–<lpage>6</lpage><pub-id pub-id-type="pmid">26309370</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B15">
<label>15</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Jankovic Velickovic</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Katic</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Hattori</surname><given-names>T</given-names></name></person-group>, <etal>et al</etal>
<article-title>Differences in the expression of mucins in various forms of cystitis glandularis</article-title>. <source/>Pathol Res Pract<year>2007</year>;<volume>203</volume>:<fpage>653</fpage>–<lpage>8</lpage><pub-id pub-id-type="pmid">17659847</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B16">
<label>16</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Buisine</surname><given-names>MP</given-names></name>, <name name-style="western"><surname>Desreumaux</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Leteurtre</surname><given-names>E</given-names></name></person-group>, <etal>et al</etal>
<article-title>Mucin gene expression in intestinal epithelial cells in Crohn’s disease</article-title>. <source/>Gut<year>2001</year>;<volume>49</volume>:<fpage>544</fpage>–<lpage>51</lpage><pub-id pub-id-type="pmid">11559653</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B17">
<label>17</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>de Bolos</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Real</surname><given-names>FX</given-names></name>, <name name-style="western"><surname>Lopez-Ferrer</surname><given-names>A.</given-names></name></person-group>
<article-title>Regulation of mucin and glycoconjugate expression: From normal epithelium to gastric tumors</article-title>. <source/>Front Biosci<year>2001</year>;<volume>6</volume>:<fpage>D1256</fpage>–<lpage>63</lpage><pub-id pub-id-type="pmid">11578953</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B18">
<label>18</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Kawakubo</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ito</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Okimura</surname><given-names>Y</given-names></name></person-group>, <etal>et al</etal>
<article-title>Natural antibiotic function of a human gastric mucin against <italic>Helicobacter pylori</italic> infection</article-title>. <source/>Science<year>2004</year>;<volume>305</volume>:<fpage>1003</fpage>–<lpage>6</lpage><pub-id pub-id-type="pmid">15310903</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B19">
<label>19</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Nguyen</surname><given-names>TV</given-names></name>, <name name-style="western"><surname>Janssen</surname><given-names>M</given-names><suffix>Jr</suffix></name>, <name name-style="western"><surname>Gritters</surname><given-names>P</given-names></name></person-group>, <etal>et al</etal>
<article-title>Short mucin 6 alleles are associated with <italic>H. pylori</italic> infection</article-title>. <source/>World J Gastroenterol<year>2006</year>;<volume>12</volume>:<fpage>6021</fpage>–<lpage>5</lpage><pub-id pub-id-type="pmid">17009402</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B20">
<label>20</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>McGuckin</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Linden</surname><given-names>SK</given-names></name>, <name name-style="western"><surname>Sutton</surname><given-names>P</given-names></name></person-group>, <etal>et al</etal>
<article-title>Mucin dynamics and enteric pathogens</article-title>. <source/>Nat Rev Microbiol<year>2011</year>;<volume>9</volume>:<fpage>265</fpage>–<lpage>78</lpage><pub-id pub-id-type="pmid">21407243</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B21">
<label>21</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Cone</surname><given-names>RA.</given-names></name></person-group>
<article-title>Barrier properties of mucus</article-title>. <source/>Adv Drug Deliv Rev<year>2009</year>;<volume>61</volume>:<fpage>75</fpage>–<lpage>85</lpage><pub-id pub-id-type="pmid">19135107</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B22">
<label>22</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Linden</surname><given-names>SK</given-names></name>, <name name-style="western"><surname>Sutton</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Karlsson</surname><given-names>NG</given-names></name></person-group>, <etal>et al</etal>
<article-title>Mucins in the mucosal barrier to infection</article-title>. <source/>Mucosal Immunol<year>2008</year>;<volume>1</volume>:<fpage>183</fpage>–<lpage>97</lpage><pub-id pub-id-type="pmid">19079178</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B23">
<label>23</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Ji</surname><given-names>HF.</given-names></name></person-group>
<article-title>Alzheimer’s disease histological and behavioral manifestations in transgenic mice correlate with specific gut microbiome state</article-title>. <source/>J Alzheimers Dis<year>2017</year>;<volume>56</volume>:<fpage>385</fpage>–<lpage>90</lpage><pub-id pub-id-type="pmid">27911317</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B24">
<label>24</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Kohler</surname><given-names>CA</given-names></name>, <name name-style="western"><surname>Maes</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Slyepchenko</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal>
<article-title>The gut-brain axis, including the microbiome, leaky gut and bacterial translocation: Mechanisms and pathophysiological role in Alzheimer’s disease</article-title>. <source/>Curr Pharm Des<year>2016</year>;<volume>22</volume>:<fpage>6152</fpage>–<lpage>66</lpage><pub-id pub-id-type="pmid">27604604</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B25">
<label>25</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Bhattacharjee</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Lukiw</surname><given-names>WJ.</given-names></name></person-group>
<article-title>Alzheimer’s disease and the microbiome</article-title>. <source/>Front Cell Neurosci<year>2013</year>;<volume>7</volume>:<fpage>153</fpage><pub-id pub-id-type="pmid">24062644</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B26">
<label>26</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Ball</surname><given-names>MJ.</given-names></name></person-group>
<article-title>The essential lesion of Alzheimer disease: A surprise in retrospect</article-title>. <source/>J Alzheimers Dis<year>2006</year>;<volume>9</volume>:<fpage>29</fpage>–<lpage>33</lpage><pub-id pub-id-type="pmid">16914842</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B27">
<label>27</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Haas</surname><given-names>JG</given-names></name>, <name name-style="western"><surname>Lathe</surname><given-names>R.</given-names></name></person-group>
<article-title>Microbes and Alzheimer’s disease: New findings call for a paradigm change</article-title>. <source/>Trends Neurosci<year>2018</year>;<volume>41</volume>:<fpage>570</fpage>–<lpage>3</lpage><pub-id pub-id-type="pmid">30033181</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B28">
<label>28</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Hill</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Clement</surname><given-names>C</given-names></name></person-group>, <etal>et al</etal>
<article-title>HSV-1 infection of human brain cells induces miRNA-146a and Alzheimer-type inflammatory signaling</article-title>. <source/>Neuroreport<year>2009</year>;<volume>20</volume>:<fpage>1500</fpage>–<lpage>5</lpage><pub-id pub-id-type="pmid">19801956</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B29">
<label>29</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Piacentini</surname><given-names>R</given-names></name>, <name name-style="western"><surname>De Chiara</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Li Puma</surname><given-names>DD</given-names></name></person-group>, <etal>et al</etal>
<article-title>HSV-1 and Alzheimer’s disease: More than a hypothesis</article-title>. <source/>Front Pharmacol<year>2014</year>;<volume>5</volume>:<fpage>97</fpage><pub-id pub-id-type="pmid">24847267</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B30">
<label>30</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Readhead</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Haure-Mirande</surname><given-names>JV</given-names></name>, <name name-style="western"><surname>Funk</surname><given-names>CC</given-names></name></person-group>, <etal>et al</etal>
<article-title>Multiscale analysis of independent Alzheimer’s cohorts finds disruption of molecular, genetic, and clinical networks by human herpesvirus</article-title>. <source/>Neuron<year>2018</year>;<volume>99</volume>:<fpage>64</fpage>–<lpage>82 e7</lpage><pub-id pub-id-type="pmid">29937276</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B31">
<label>31</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Salas</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Pardo-Seco</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Cebey-Lopez</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal>
<article-title>Whole exome sequencing reveals new candidate genes in host genomic susceptibility to respiratory syncytial virus disease</article-title>. <source/>Sci Rep<year>2017</year>;<volume>7</volume>:<fpage>15888</fpage><pub-id pub-id-type="pmid">29162850</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B32">
<label>32</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Allnutt</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Johnson</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Bennett</surname><given-names>DA</given-names></name></person-group>, <etal>et al</etal>
<article-title>Human herpesvirus 6 detection in Alzheimer’s disease cases and controls across multiple cohorts</article-title>. <source/>Neuron<year>2020</year>;<volume>105</volume>:1027–35 e2</mixed-citation>
</ref>
<ref id="nlaa024-B33">
<label>33</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>McMahon</surname><given-names>HT</given-names></name>, <name name-style="western"><surname>Boucrot</surname><given-names>E.</given-names></name></person-group>
<article-title>Molecular mechanism and physiological functions of clathrin-mediated endocytosis</article-title>. <source/>Nat Rev Mol Cell Biol<year>2011</year>;<volume>12</volume>:<fpage>517</fpage>–<lpage>33</lpage><pub-id pub-id-type="pmid">21779028</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B34">
<label>34</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Boehm</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Bonifacino</surname><given-names>JS.</given-names></name></person-group>
<article-title>Adaptins: The final recount</article-title>. <source/>Mol Biol Cell<year>2001</year>;<volume>12</volume>:<fpage>2907</fpage>–<lpage>20</lpage><pub-id pub-id-type="pmid">11598180</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B35">
<label>35</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Rodemer</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Haucke</surname><given-names>V.</given-names></name></person-group>
<article-title>Clathrin/AP-2-dependent endocytosis: A novel playground for the pharmacological toolbox?</article-title>
<source/>Handb Exp Pharmacol
<year>2008</year>;<fpage>186:105</fpage>–<lpage>22</lpage></mixed-citation>
</ref>
<ref id="nlaa024-B36">
<label>36</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Ohno</surname><given-names>H.</given-names></name></person-group>
<article-title>Physiological roles of clathrin adaptor AP complexes: Lessons from mutant animals</article-title>. <source/>J Biochem<year>2006</year>;<volume>139</volume>:<fpage>943</fpage>–<lpage>8</lpage><pub-id pub-id-type="pmid">16788044</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B37">
<label>37</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Dergai</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Iershov</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Novokhatska</surname><given-names>O</given-names></name></person-group>, <etal>et al</etal>
<article-title>Evolutionary changes on the way to clathrin-mediated endocytosis in animals</article-title>. <source/>Genome Biol Evol<year>2016</year>;<volume>8</volume>:<fpage>588</fpage>–<lpage>606</lpage><pub-id pub-id-type="pmid">26872775</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B38">
<label>38</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Kratzke</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Candiello</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Schmidt</surname><given-names>B</given-names></name></person-group>, <etal>et al</etal>
<article-title>AP-1/sigma1B-dependent SV protein recycling is regulated in early endosomes and is coupled to AP-2 endocytosis</article-title>. <source/>Mol Neurobiol<year>2015</year>;<volume>52</volume>:<fpage>142</fpage>–<lpage>61</lpage><pub-id pub-id-type="pmid">25128028</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B39">
<label>39</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Hirst</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Robinson</surname><given-names>MS.</given-names></name></person-group>
<article-title>Clathrin and adaptors</article-title>. <source/>Biochim Biophys Acta<year>1998</year>;<volume>1404</volume>:<fpage>173</fpage>–<lpage>93</lpage><pub-id pub-id-type="pmid">9714795</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B40">
<label>40</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Malki</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Cantrelle</surname><given-names>FX</given-names></name>, <name name-style="western"><surname>Sottejeau</surname><given-names>Y</given-names></name></person-group>, <etal>et al</etal>
<article-title>Regulation of the interaction between the neuronal BIN1 isoform 1 and tau proteins – role of the SH3 domain</article-title>. <source/>FEBS J<year>2017</year>;<volume>284</volume>:<fpage>3218</fpage>–<lpage>29</lpage><pub-id pub-id-type="pmid">28755476</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B41">
<label>41</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Tian</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Chang</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Fan</surname><given-names>EY</given-names></name></person-group>, <etal>et al</etal>
<article-title>Adaptor complex AP2/PICALM, through interaction with LC3, targets Alzheimer’s APP-CTF for terminal degradation via autophagy</article-title>. <source/>Proc Natl Acad Sci U S A<year>2013</year>;<volume>110</volume>:<fpage>17071</fpage>–<lpage>6</lpage><pub-id pub-id-type="pmid">24067654</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B42">
<label>42</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Azarnia Tehran</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Kuijpers</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Haucke</surname><given-names>V.</given-names></name></person-group>
<article-title>Presynaptic endocytic factors in autophagy and neurodegeneration</article-title>. <source/>Curr Opin Neurobiol<year>2018</year>;<volume>48</volume>:<fpage>153</fpage>–<lpage>9</lpage><pub-id pub-id-type="pmid">29316491</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B43">
<label>43</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Van Acker</surname><given-names>ZP</given-names></name>, <name name-style="western"><surname>Bretou</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Annaert</surname><given-names>W.</given-names></name></person-group>
<article-title>Endo-lysosomal dysregulations and late-onset Alzheimer’s disease: Impact of genetic risk factors</article-title>. <source/>Mol Neurodegener<year>2019</year>;<volume>14</volume>:<fpage>20</fpage><pub-id pub-id-type="pmid">31159836</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B44">
<label>44</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Azarnia Tehran</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Lopez-Hernandez</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Maritzen</surname><given-names>T.</given-names></name></person-group>
<article-title>Endocytic adaptor proteins in health and disease: Lessons from model organisms and human mutations</article-title>. <source/>Cells<year>2019</year>;<volume>8</volume>:<fpage>1</fpage>–52</mixed-citation>
</ref>
<ref id="nlaa024-B45">
<label>45</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Poulsen</surname><given-names>ET</given-names></name>, <name name-style="western"><surname>Iannuzzi</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Rasmussen</surname><given-names>HF</given-names></name></person-group>, <etal>et al</etal>
<article-title>An aberrant phosphorylation of amyloid precursor protein tyrosine regulates its trafficking and the binding to the clathrin endocytic complex in neural stem cells of Alzheimer’s disease patients</article-title>. <source/>Front Mol Neurosci<year>2017</year>;<volume>10</volume>:<fpage>59</fpage><pub-id pub-id-type="pmid">28360834</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B46">
<label>46</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Marcello</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Saraceno</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Musardo</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal>
<article-title>Endocytosis of synaptic ADAM10 in neuronal plasticity and Alzheimer’s disease</article-title>. <source/>J Clin Invest<year>2013</year>;<volume>123</volume>:<fpage>2523</fpage>–<lpage>38</lpage><pub-id pub-id-type="pmid">23676497</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B47">
<label>47</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Prabhu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Burgos</surname><given-names>PV</given-names></name>, <name name-style="western"><surname>Schindler</surname><given-names>C</given-names></name></person-group>, <etal>et al</etal>
<article-title>Adaptor protein 2-mediated endocytosis of the beta-secretase BACE1 is dispensable for amyloid precursor protein processing</article-title>. <source/>Mol Biol Cell<year>2012</year>;<volume>23</volume>:<fpage>2339</fpage>–<lpage>51</lpage><pub-id pub-id-type="pmid">22553349</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B48">
<label>48</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Holtzman</surname><given-names>DM</given-names></name>, <name name-style="western"><surname>Herz</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Bu</surname><given-names>G.</given-names></name></person-group>
<article-title>Apolipoprotein E and apolipoprotein E receptors: Normal biology and roles in Alzheimer disease</article-title>. <source/>Cold Spring Harb Perspect Med<year>2012</year>;<volume>2</volume>:<fpage>a006312</fpage><pub-id pub-id-type="pmid">22393530</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B49">
<label>49</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Boucrot</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Saffarian</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>R</given-names></name></person-group>, <etal>et al</etal>
<article-title>Roles of AP-2 in clathrin-mediated endocytosis</article-title>. <source/>PLoS One<year>2010</year>;<volume>5</volume>:<fpage>e10597</fpage><pub-id pub-id-type="pmid">20485680</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B50">
<label>50</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Garuti</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Jones</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>WP</given-names></name></person-group>, <etal>et al</etal>
<article-title>The modular adaptor protein autosomal recessive hypercholesterolemia (ARH) promotes low density lipoprotein receptor clustering into clathrin-coated pits</article-title>. <source/>J Biol Chem<year>2005</year>;<volume>280</volume>:<fpage>40996</fpage>–<lpage>1004</lpage><pub-id pub-id-type="pmid">16179341</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B51">
<label>51</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Beacham</surname><given-names>GM</given-names></name>, <name name-style="western"><surname>Partlow</surname><given-names>EA</given-names></name>, <name name-style="western"><surname>Hollopeter</surname><given-names>G.</given-names></name></person-group>
<article-title>Conformational regulation of AP1 and AP2 clathrin adaptor complexes</article-title>. <source/>Traffic<year>2019</year>;<volume>20</volume>:<fpage>741</fpage>–<lpage>51</lpage><pub-id pub-id-type="pmid">31313456</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B52">
<label>52</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Agrelli</surname><given-names>A</given-names></name>, <name name-style="western"><surname>de Moura</surname><given-names>RR</given-names></name>, <name name-style="western"><surname>Crovella</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal>
<article-title>ZIKA virus entry mechanisms in human cells</article-title>. <source/>Infect Genet Evol<year>2019</year>;<volume>69</volume>:<fpage>22</fpage>–<lpage>9</lpage><pub-id pub-id-type="pmid">30658214</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B53">
<label>53</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Mercer</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Schelhaas</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Helenius</surname><given-names>A.</given-names></name></person-group>
<article-title>Virus entry by endocytosis</article-title>. <source/>Annu Rev Biochem<year>2010</year>;<volume>79</volume>:<fpage>803</fpage>–<lpage>33</lpage><pub-id pub-id-type="pmid">20196649</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B54">
<label>54</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Byland</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Vance</surname><given-names>PJ</given-names></name>, <name name-style="western"><surname>Hoxie</surname><given-names>JA</given-names></name></person-group>, <etal>et al</etal>
<article-title>A conserved dileucine motif mediates clathrin and AP-2-dependent endocytosis of the HIV-1 envelope protein</article-title>. <source/>Mol Biol Cell<year>2007</year>;<volume>18</volume>:<fpage>414</fpage>–<lpage>25</lpage><pub-id pub-id-type="pmid">17108326</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B55">
<label>55</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Consortium</surname><given-names>GT.</given-names></name></person-group>
<article-title>The genotype-tissue expression (GTEx) project</article-title>. <source/>Nat Genet<year>2013</year>;<volume>45</volume>:<fpage>580</fpage>–<lpage>5</lpage><pub-id pub-id-type="pmid">23715323</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B56">
<label>56</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Braak</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Braak</surname><given-names>E.</given-names></name></person-group>
<article-title>Staging of Alzheimer’s disease-related neurofibrillary changes</article-title>. <source/>Neurobiol Aging<year>1995</year>;<volume>16</volume>:<fpage>271</fpage>–<lpage>8,</lpage> Discussion <fpage>8</fpage>–<lpage>84</lpage><pub-id pub-id-type="pmid">7566337</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B57">
<label>57</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Thal</surname><given-names>DR</given-names></name>, <name name-style="western"><surname>Rub</surname><given-names>U</given-names></name>, <name name-style="western"><surname>Orantes</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal>
<article-title>Phases of A beta-deposition in the human brain and its relevance for the development of AD</article-title>. <source/>Neurology<year>2002</year>;<volume>58</volume>:<fpage>1791</fpage>–<lpage>800</lpage><pub-id pub-id-type="pmid">12084879</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B58">
<label>58</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Ando</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Tomimura</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Sazdovitch</surname><given-names>V</given-names></name></person-group>, <etal>et al</etal>
<article-title>Level of PICALM, a key component of clathrin-mediated endocytosis, is correlated with levels of phosphotau and autophagy-related proteins and is associated with tau inclusions in AD, PSP and Pick disease</article-title>. <source/>Neurobiol Dis<year>2016</year>;<volume>94</volume>:<fpage>32</fpage>–<lpage>43</lpage><pub-id pub-id-type="pmid">27260836</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B59">
<label>59</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Haraksingh</surname><given-names>RR</given-names></name>, <name name-style="western"><surname>Snyder</surname><given-names>MP.</given-names></name></person-group>
<article-title>Impacts of variation in the human genome on gene regulation</article-title>. <source/>J Mol Biol<year>2013</year>;<volume>425</volume>:<fpage>3970</fpage>–<lpage>7</lpage><pub-id pub-id-type="pmid">23871684</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B60">
<label>60</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Lambert</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Ibrahim-Verbaas</surname><given-names>CA</given-names></name>, <name name-style="western"><surname>Harold</surname><given-names>D</given-names></name></person-group>, <etal>et al</etal>
<article-title>Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease</article-title>. <source/>Nat Genet<year>2013</year>;<volume>45</volume>:<fpage>1452</fpage>–<lpage>8</lpage><pub-id pub-id-type="pmid">24162737</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B61">
<label>61</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Espinosa</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Hernandez-Olasagarre</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Moreno-Grau</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal>
<article-title>Exploring genetic associations of Alzheimer’s disease loci with mild cognitive impairment neurocognitive endophenotypes</article-title>. <source/>Front Aging Neurosci<year>2018</year>;<volume>10</volume>:<fpage>340</fpage><pub-id pub-id-type="pmid">30425636</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B62">
<label>62</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Nazarian</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Yashin</surname><given-names>AI</given-names></name>, <name name-style="western"><surname>Kulminski</surname><given-names>AM.</given-names></name></person-group>
<article-title>Genome-wide analysis of genetic predisposition to Alzheimer’s disease and related sex disparities</article-title>. <source/>Alzheimers Res Ther<year>2019</year>;<volume>11</volume>:<fpage>5</fpage><pub-id pub-id-type="pmid">30636644</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B63">
<label>63</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Jansen</surname><given-names>IE</given-names></name>, <name name-style="western"><surname>Savage</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Watanabe</surname><given-names>K</given-names></name></person-group>, <etal>et al</etal>
<article-title>Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk</article-title>. <source/>Nat Genet<year>2019</year>;<volume>51</volume>:<fpage>404</fpage>–<lpage>13</lpage><pub-id pub-id-type="pmid">30617256</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B64">
<label>64</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Kunkle</surname><given-names>BW</given-names></name>, <name name-style="western"><surname>Grenier-Boley</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Sims</surname><given-names>R</given-names></name></person-group>, <etal>et al</etal>
<article-title>Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Abeta, tau, immunity and lipid processing</article-title>. <source/>Nat Genet<year>2019</year>;<volume>51</volume>:<fpage>414</fpage>–<lpage>30</lpage><pub-id pub-id-type="pmid">30820047</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B65">
<label>65</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Marioni</surname><given-names>RE</given-names></name>, <name name-style="western"><surname>Harris</surname><given-names>SE</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></name></person-group>, <etal>et al</etal>
<article-title>GWAS on family history of Alzheimer’s disease</article-title>. <source/>Transl Psychiatry<year>2018</year>;<volume>8</volume>:<fpage>99</fpage><pub-id pub-id-type="pmid">29777097</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B66">
<label>66</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Raj</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>YI</given-names></name>, <name name-style="western"><surname>Wong</surname><given-names>G</given-names></name></person-group>, <etal>et al</etal>
<article-title>Integrative transcriptome analyses of the aging brain implicate altered splicing in Alzheimer’s disease susceptibility</article-title>. <source/>Nat Genet<year>2018</year>;<volume>50</volume>:<fpage>1584</fpage>–<lpage>92</lpage><pub-id pub-id-type="pmid">30297968</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B67">
<label>67</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Hao</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name></person-group>, <etal>et al</etal>
<article-title>Prediction of Alzheimer’s disease-associated genes by integration of GWAS summary data and expression data</article-title>. <source/>Front Genet<year>2018</year>;<volume>9</volume>:<fpage>653</fpage><pub-id pub-id-type="pmid">30666269</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B68">
<label>68</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Ashley-Koch</surname><given-names>AE</given-names></name>, <name name-style="western"><surname>Shao</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Rimmler</surname><given-names>JB</given-names></name></person-group>, <etal>et al</etal>
<article-title>An autosomal genomic screen for dementia in an extended Amish family</article-title>. <source/>Neurosci Lett<year>2005</year>;<volume>379</volume>:<fpage>199</fpage>–<lpage>204</lpage><pub-id pub-id-type="pmid">15843063</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B69">
<label>69</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Casey</surname><given-names>AE</given-names></name>, <name name-style="western"><surname>Sargeant</surname><given-names>TJ</given-names></name></person-group>, <etal>et al</etal>
<article-title>Genetic variation within endolysosomal system is associated with late-onset Alzheimer’s disease</article-title>. <source/>Brain<year>2018</year>;<volume>141</volume>:<fpage>2711</fpage>–<lpage>20</lpage><pub-id pub-id-type="pmid">30124770</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B70">
<label>70</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Morgan</surname><given-names>K.</given-names></name></person-group>
<article-title>The three new pathways leading to Alzheimer’s disease</article-title>. <source/>Neuropathol Appl Neurobiol<year>2011</year>;<volume>37</volume>:<fpage>353</fpage>–<lpage>7</lpage><pub-id pub-id-type="pmid">21486313</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B71">
<label>71</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Kimura</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Yanagisawa</surname><given-names>K.</given-names></name></person-group>
<article-title>Traffic jam hypothesis: Relationship between endocytic dysfunction and Alzheimer’s disease</article-title>. <source/>Neurochem Int<year>2018</year>;<volume>119</volume>:<fpage>35</fpage>–<lpage>41</lpage><pub-id pub-id-type="pmid">28697973</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B72">
<label>72</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Small</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Simoes-Spassov</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Mayeux</surname><given-names>R</given-names></name></person-group>, <etal>et al</etal>
<article-title>Endosomal traffic jams represent a pathogenic hub and therapeutic target in Alzheimer’s disease</article-title>. <source/>Trends Neurosci<year>2017</year>;<volume>40</volume>:<fpage>592</fpage>–<lpage>602</lpage><pub-id pub-id-type="pmid">28962801</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B73">
<label>73</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Andrews</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Fulton-Howard</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Goate</surname><given-names>A.</given-names></name></person-group>
<article-title>Interpretation of risk loci from genome-wide association studies of Alzheimer’s disease</article-title>. <source/>Lancet Neurol<year>2020</year>; doi: 10.1016/S1474-4422(19)30435-1</mixed-citation>
</ref>
<ref id="nlaa024-B74">
<label>74</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Holler</surname><given-names>CJ</given-names></name>, <name name-style="western"><surname>Davis</surname><given-names>PR</given-names></name>, <name name-style="western"><surname>Beckett</surname><given-names>TL</given-names></name></person-group>, <etal>et al</etal>
<article-title>Bridging integrator 1 (BIN1) protein expression increases in the Alzheimer’s disease brain and correlates with neurofibrillary tangle pathology</article-title>. <source/>J Alzheimers Dis<year>2014</year>;<volume>42</volume>:<fpage>1221</fpage>–<lpage>7</lpage><pub-id pub-id-type="pmid">25024306</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B75">
<label>75</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Poulsen</surname><given-names>ET</given-names></name>, <name name-style="western"><surname>Larsen</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Zollo</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal>
<article-title>New insights to clathrin and adaptor protein 2 for the design and development of therapeutic strategies</article-title>. <source/>Int J Mol Sci<year>2015</year>;<volume>16</volume>:<fpage>29446</fpage>–<lpage>53</lpage><pub-id pub-id-type="pmid">26690411</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B76">
<label>76</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Baig</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Joseph</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Tayler</surname><given-names>H</given-names></name></person-group>, <etal>et al</etal>
<article-title>Distribution and expression of picalm in Alzheimer disease</article-title>. <source/>J Neuropathol Exp Neurol<year>2010</year>;<volume>69</volume>:<fpage>1071</fpage>–<lpage>7</lpage><pub-id pub-id-type="pmid">20838239</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B77">
<label>77</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Heckmann</surname><given-names>BL</given-names></name>, <name name-style="western"><surname>Teubner</surname><given-names>BJW</given-names></name>, <name name-style="western"><surname>Tummers</surname><given-names>B</given-names></name></person-group>, <etal>et al</etal>
<article-title>LC3-associated endocytosis facilitates beta-amyloid clearance and mitigates neurodegeneration in murine Alzheimer’s disease</article-title>. <source/>Cell<year>2019</year>;<volume>178</volume>:<fpage>536</fpage>–<lpage>51.e14</lpage><pub-id pub-id-type="pmid">31257024</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B78">
<label>78</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Juul Rasmussen</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Tybjærg-Hansen</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Rasmussen</surname><given-names>KL</given-names></name></person-group>, <etal>et al</etal>
<article-title>Blood-brain barrier transcytosis genes, risk of dementia and stroke: A prospective cohort study of 74,754 individuals</article-title>. <source/>Eur J Epidemiol<year>2019</year>;<volume>34</volume>:<fpage>579</fpage>–<lpage>90</lpage><pub-id pub-id-type="pmid">30830563</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B79">
<label>79</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Bakhtiari</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Shleizer-Burko</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Gymrek</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal>
<article-title>Targeted genotyping of variable number tandem repeats with adVNTR</article-title>. <source/>Genome Res<year>2018</year>;<volume>28</volume>:<fpage>1709</fpage>–<lpage>19</lpage><pub-id pub-id-type="pmid">30352806</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B80">
<label>80</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Naslund</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Saetre</surname><given-names>P</given-names></name>, <name name-style="western"><surname>von Salome</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal>
<article-title>Genome-wide prediction of human VNTRs</article-title>. <source/>Genomics<year>2005</year>;<volume>85</volume>:<fpage>24</fpage>–<lpage>35</lpage><pub-id pub-id-type="pmid">15607419</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B81">
<label>81</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Brookes</surname><given-names>KJ.</given-names></name></person-group>
<article-title>The VNTR in complex disorders: The forgotten polymorphisms? A functional way forward?</article-title>
<source/>Genomics
<year>2013</year>;<volume>101</volume>:<fpage>273</fpage>–<lpage>81</lpage><pub-id pub-id-type="pmid">23517681</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B82">
<label>82</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Lauer</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Gresham</surname><given-names>D.</given-names></name></person-group>
<article-title>An evolving view of copy number variants</article-title>. <source/>Curr Genet<year>2019</year>;<volume>65</volume>:<fpage>1287</fpage>–<lpage>95</lpage><pub-id pub-id-type="pmid">31076843</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B83">
<label>83</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Szigeti</surname><given-names>K.</given-names></name></person-group>
<article-title>New genome-wide methods for elucidation of candidate copy number variations (CNVs) contributing to Alzheimer’s disease heritability</article-title>. <source/>Methods Mol Biol<year>2016</year>;<volume>1303</volume>:<fpage>315</fpage>–<lpage>26</lpage><pub-id pub-id-type="pmid">26235076</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B84">
<label>84</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Mahmoud</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Gobet</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Cruz-Davalos</surname><given-names>DI</given-names></name></person-group>, <etal>et al</etal>
<article-title>Structural variant calling: The long and the short of it</article-title>. <source/>Genome Biol<year>2019</year>;<volume>20</volume>:<fpage>246</fpage><pub-id pub-id-type="pmid">31747936</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B85">
<label>85</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Ho</surname><given-names>SS</given-names></name>, <name name-style="western"><surname>Urban</surname><given-names>AE</given-names></name>, <name name-style="western"><surname>Mills</surname><given-names>RE.</given-names></name></person-group>
<article-title>Structural variation in the sequencing era</article-title>. <source/>Nat Rev Genet<year>2020</year>;<volume>21</volume>:<fpage>171</fpage>–<lpage>89</lpage><pub-id pub-id-type="pmid">31729472</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B86">
<label>86</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Lower</surname><given-names>SS</given-names></name>, <name name-style="western"><surname>McGurk</surname><given-names>MP</given-names></name>, <name name-style="western"><surname>Clark</surname><given-names>AG</given-names></name></person-group>, <etal>et al</etal>
<article-title>Satellite DNA evolution: Old ideas, new approaches</article-title>. <source/>Curr Opin Genet Dev<year>2018</year>;<volume>49</volume>:<fpage>70</fpage>–<lpage>8</lpage><pub-id pub-id-type="pmid">29579574</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B87">
<label>87</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Karakoc</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Alkan</surname><given-names>C</given-names></name>, <name name-style="western"><surname>O'Roak</surname><given-names>BJ</given-names></name></person-group>, <etal>et al</etal>
<article-title>Detection of structural variants and indels within exome data</article-title>. <source/>Nat Methods<year>2012</year>;<volume>9</volume>:<fpage>176</fpage>–<lpage>8</lpage></mixed-citation>
</ref>
<ref id="nlaa024-B88">
<label>88</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Roses</surname><given-names>AD</given-names></name>, <name name-style="western"><surname>Akkari</surname><given-names>PA</given-names></name>, <name name-style="western"><surname>Chiba-Falek</surname><given-names>O</given-names></name></person-group>, <etal>et al</etal>
<article-title>Structural variants can be more informative for disease diagnostics, prognostics and translation than current SNP mapping and exon sequencing</article-title>. <source/>Expert Opin Drug Metab Toxicol<year>2016</year>;<volume>12</volume>:<fpage>135</fpage>–<lpage>47</lpage><pub-id pub-id-type="pmid">26727306</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B89">
<label>89</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Ciesiolka</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Jazurek</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Drazkowska</surname><given-names>K</given-names></name></person-group>, <etal>et al</etal>
<article-title>Structural characteristics of simple RNA repeats associated with disease and their deleterious protein interactions</article-title>. <source/>Front Cell Neurosci<year>2017</year>;<volume>11</volume>:<fpage>97</fpage><pub-id pub-id-type="pmid">28442996</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B90">
<label>90</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Nakamura</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Koyama</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Matsushima</surname><given-names>M.</given-names></name></person-group>
<article-title>VNTR (variable number of tandem repeat) sequences as transcriptional, translational, or functional regulators</article-title>. <source/>J Hum Genet<year>1998</year>;<volume>43</volume>:<fpage>149</fpage>–<lpage>52</lpage><pub-id pub-id-type="pmid">9747025</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B91">
<label>91</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Marogianni</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Rikos</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Provatas</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal>
<article-title>The role of C9orf72 in neurodegenerative disorders: A systematic review, an updated meta-analysis, and the creation of an online database</article-title>. <source/>Neurobiol Aging<year>2019</year>;<volume>84</volume>:238 <fpage>e25</fpage>–<lpage>e34</lpage></mixed-citation>
</ref>
<ref id="nlaa024-B92">
<label>92</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Laaksovirta</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Peuralinna</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Schymick</surname><given-names>JC</given-names></name></person-group>, <etal>et al</etal>
<article-title>Chromosome 9p21 in amyotrophic lateral sclerosis in Finland: A genome-wide association study</article-title>. <source/>Lancet Neurol<year>2010</year>;<volume>9</volume>:<fpage>978</fpage>–<lpage>85</lpage><pub-id pub-id-type="pmid">20801718</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B93">
<label>93</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Shatunov</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Mok</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Newhouse</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal>
<article-title>Chromosome 9p21 in sporadic amyotrophic lateral sclerosis in the UK and seven other countries: A genome-wide association study</article-title>. <source/>Lancet Neurol<year>2010</year>;<volume>9</volume>:<fpage>986</fpage>–<lpage>94</lpage><pub-id pub-id-type="pmid">20801717</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B94">
<label>94</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>van Es</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Veldink</surname><given-names>JH</given-names></name>, <name name-style="western"><surname>Saris</surname><given-names>CG</given-names></name></person-group>, <etal>et al</etal>
<article-title>Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis</article-title>. <source/>Nat Genet<year>2009</year>;<volume>41</volume>:<fpage>1083</fpage>–<lpage>7</lpage><pub-id pub-id-type="pmid">19734901</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B95">
<label>95</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Svensson</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Lang</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Johansson</surname><given-names>MEV</given-names></name></person-group>, <etal>et al</etal>
<article-title>The central exons of the human MUC2 and MUC6 mucins are highly repetitive and variable in sequence between individuals</article-title>. <source/>Sci Rep<year>2018</year>;<volume>8</volume>:<fpage>17503</fpage><pub-id pub-id-type="pmid">30504806</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B96">
<label>96</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Ahn</surname><given-names>MH</given-names></name>, <name name-style="western"><surname>Bae</surname><given-names>KB</given-names></name>, <name name-style="western"><surname>Kwon</surname><given-names>JA</given-names></name></person-group>, <etal>et al</etal>
<article-title>Association of MUC6-minisatellite variants with susceptibility to rectal carcinoma</article-title>. <source/>Mol Biol Rep<year>2013</year>;<volume>40</volume>:<fpage>303</fpage>–<lpage>8</lpage><pub-id pub-id-type="pmid">23054008</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B97">
<label>97</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Parry</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Sutton-Smith</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Heal</surname><given-names>P</given-names></name></person-group>, <etal>et al</etal>
<article-title>Evaluation of MUC6 mucin tandem repeats</article-title>. <source/>Biochim Biophys Acta<year>2005</year>;<volume>1722</volume>:<fpage>77</fpage>–<lpage>83</lpage><pub-id pub-id-type="pmid">15716126</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B98">
<label>98</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Vinall</surname><given-names>LE</given-names></name>, <name name-style="western"><surname>Hill</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Pigny</surname><given-names>P</given-names></name></person-group>, <etal>et al</etal>
<article-title>Variable number tandem repeat polymorphism of the mucin genes located in the complex on 11p15.5</article-title>. <source/>Hum Genet<year>1998</year>;<volume>102</volume>:<fpage>357</fpage>–<lpage>66</lpage><pub-id pub-id-type="pmid">9544852</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B99">
<label>99</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Garcia</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Carvalho</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Amorim</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal>
<article-title>MUC6 gene polymorphism in healthy individuals and in gastric cancer patients from northern Portugal</article-title>. <source/>Cancer Epidemiol Biomarkers Prev<year>1997</year>;<volume>6</volume>:<fpage>1071</fpage>–<lpage>4</lpage><pub-id pub-id-type="pmid">9419405</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B100">
<label>100</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Bobek</surname><given-names>LA</given-names></name>, <name name-style="western"><surname>Tsai</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Biesbrock</surname><given-names>AR</given-names></name></person-group>, <etal>et al</etal>
<article-title>Molecular cloning, sequence, and specificity of expression of the gene encoding the low molecular weight human salivary mucin (MUC7)</article-title>. <source/>J Biol Chem<year>1993</year>;<volume>268</volume>:<fpage>20563</fpage>–<lpage>9</lpage><pub-id pub-id-type="pmid">7690757</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B101">
<label>101</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Toribara</surname><given-names>NW</given-names></name>, <name name-style="western"><surname>Ho</surname><given-names>SB</given-names></name>, <name name-style="western"><surname>Gum</surname><given-names>E</given-names></name></person-group>, <etal>et al</etal>
<article-title>The carboxyl-terminal sequence of the human secretory mucin, MUC6. Analysis Of the primary amino acid sequence</article-title>. <source/>J Biol Chem<year>1997</year>;<volume>272</volume>:<fpage>16398</fpage>–<lpage>403</lpage><pub-id pub-id-type="pmid">9195947</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B102">
<label>102</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Yamazaki</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Tajima</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Makino</surname><given-names>R</given-names></name></person-group>, <etal>et al</etal>
<article-title>Tumor differentiation phenotype in gastric differentiated-type tumors and its relation to tumor invasion and genetic alterations</article-title>. <source/>World J Gastroenterol<year>2006</year>;<volume>12</volume>:<fpage>3803</fpage>–<lpage>9</lpage><pub-id pub-id-type="pmid">16804962</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B103">
<label>103</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Kwon</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>SY</given-names></name>, <name name-style="western"><surname>Ahn</surname><given-names>EK</given-names></name></person-group>, <etal>et al</etal>
<article-title>Short rare MUC6 minisatellites-5 alleles influence susceptibility to gastric carcinoma by regulating gene</article-title>. <source/>Hum Mutat<year>2010</year>;<volume>31</volume>:<fpage>942</fpage>–<lpage>9</lpage><pub-id pub-id-type="pmid">20506113</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B104">
<label>104</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Troxler</surname><given-names>RF</given-names></name>, <name name-style="western"><surname>Iontcheva</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Oppenheim</surname><given-names>FG</given-names></name></person-group>, <etal>et al</etal>
<article-title>Molecular characterization of a major high molecular weight mucin from human sublingual gland</article-title>. <source/>Glycobiology<year>1997</year>;<volume>7</volume>:<fpage>965</fpage>–<lpage>73</lpage><pub-id pub-id-type="pmid">9363439</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B105">
<label>105</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Crane</surname><given-names>PK</given-names></name>, <name name-style="western"><surname>Foroud</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Montine</surname><given-names>TJ</given-names></name></person-group>, <etal>et al</etal>
<article-title>Alzheimer’s Disease Sequencing Project discovery and replication criteria for cases and controls: Data from a community-based prospective cohort study with autopsy follow-up</article-title>. <source/>Alzheimers Dement<year>2017</year>;<volume>13</volume>:<fpage>1410</fpage>–<lpage>3</lpage><pub-id pub-id-type="pmid">29055816</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B106">
<label>106</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Naj</surname><given-names>AC</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Vardarajan</surname><given-names>BN</given-names></name></person-group>, <etal>et al</etal>
<article-title>Quality control and integration of genotypes from two calling pipelines for whole genome sequence data in the Alzheimer’s disease sequencing project</article-title>. <source/>Genomics<year>2019</year>;<volume>111</volume>:<fpage>808</fpage>–<lpage>18</lpage><pub-id pub-id-type="pmid">29857119</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B107">
<label>107</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Bavarva</surname><given-names>JH</given-names></name>, <name name-style="western"><surname>Tae</surname><given-names>H</given-names></name>, <name name-style="western"><surname>McIver</surname><given-names>L</given-names></name></person-group>, <etal>et al</etal>
<article-title>The dynamic exome: Acquired variants as individuals age</article-title>. <source/>Aging<year>2014</year>;<volume>6</volume>:<fpage>511</fpage>–<lpage>21</lpage><pub-id pub-id-type="pmid">25063753</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B108">
<label>108</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Toribara</surname><given-names>NW</given-names></name>, <name name-style="western"><surname>Gum</surname><given-names>JR</given-names><suffix>Jr</suffix></name>, <name name-style="western"><surname>Culhane</surname><given-names>PJ</given-names></name></person-group>, <etal>et al</etal>
<article-title>MUC-2 human small intestinal mucin gene structure. Repeated arrays and polymorphism</article-title>. <source/>J Clin Invest<year>1991</year>;<volume>88</volume>:<fpage>1005</fpage>–<lpage>13</lpage><pub-id pub-id-type="pmid">1885763</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B109">
<label>109</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Kwak</surname><given-names>SH</given-names></name>, <name name-style="western"><surname>Chae</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Choi</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal>
<article-title>Findings of a 1303 Korean whole-exome sequencing study</article-title>. <source/>Exp Mol Med<year>2017</year>;<volume>49</volume>:<fpage>e356</fpage><pub-id pub-id-type="pmid">28706299</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B110">
<label>110</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Hsieh</surname><given-names>SW</given-names></name>, <name name-style="western"><surname>Chang</surname><given-names>YH</given-names></name></person-group>, <etal>et al</etal>
<article-title>Differences in the frequency of Alzheimer’s disease-associated genomic variations in populations of different races</article-title>. <source/>Geriatr Gerontol Int<year>2017</year>;<volume>17</volume>:<fpage>2184</fpage>–<lpage>93</lpage><pub-id pub-id-type="pmid">28675603</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B111">
<label>111</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Vardarajan</surname><given-names>BN</given-names></name>, <name name-style="western"><surname>Barral</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Jaworski</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal>
<article-title>Whole genome sequencing of Caribbean Hispanic families with late-onset Alzheimer’s disease</article-title>. <source/>Ann Clin Transl Neurol<year>2018</year>;<volume>5</volume>:<fpage>406</fpage>–<lpage>17</lpage><pub-id pub-id-type="pmid">29688227</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B112">
<label>112</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Reitz</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Mayeux</surname><given-names>R.</given-names></name></person-group>
<article-title>Genetics of Alzheimer’s disease in Caribbean Hispanic and African American populations</article-title>. <source/>Biol Psychiatry<year>2014</year>;<volume>75</volume>:<fpage>534</fpage>–<lpage>41</lpage><pub-id pub-id-type="pmid">23890735</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B113">
<label>113</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Miyashita</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Koike</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Jun</surname><given-names>G</given-names></name></person-group>, <etal>et al</etal>
<article-title>SORL1 is genetically associated with late-onset Alzheimer’s disease in Japanese, Koreans and Caucasians</article-title>. <source/>PLoS One<year>2013</year>;<volume>8</volume>:<fpage>e58618</fpage><pub-id pub-id-type="pmid">23565137</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B114">
<label>114</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Logue</surname><given-names>MW</given-names></name>, <name name-style="western"><surname>Lancour</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Farrell</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal>
<article-title>Targeted sequencing of Alzheimer disease genes in African Americans implicates novel risk variants</article-title>. <source/>Front Neurosci<year>2018</year>;<volume>12</volume>:<fpage>592</fpage><pub-id pub-id-type="pmid">30210277</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B115">
<label>115</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Ighodaro</surname><given-names>ET</given-names></name>, <name name-style="western"><surname>Nelson</surname><given-names>PT</given-names></name>, <name name-style="western"><surname>Kukull</surname><given-names>WA</given-names></name></person-group>, <etal>et al</etal>
<article-title>Challenges and considerations related to studying dementia in Blacks/African Americans</article-title>. <source/>J Alzheimers Dis<year>2017</year>;<volume>60</volume>:<fpage>1</fpage>–<lpage>10</lpage><pub-id pub-id-type="pmid">28731440</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B116">
<label>116</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Stocker</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Mollers</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Perna</surname><given-names>L</given-names></name></person-group>, <etal>et al</etal>
<article-title>The genetic risk of Alzheimer’s disease beyond APOE epsilon4: Systematic review of Alzheimer’s genetic risk scores</article-title>. <source/>Transl Psychiatry<year>2018</year>;<volume>8</volume>:<fpage>166</fpage><pub-id pub-id-type="pmid">30143603</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B117">
<label>117</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Tasaki</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Gaiteri</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Mostafavi</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal>
<article-title>The molecular and neuropathological consequences of genetic risk for Alzheimer’s dementia</article-title>. <source/>Front Neurosci<year>2018</year>;<volume>12</volume>:<fpage>699</fpage><pub-id pub-id-type="pmid">30349450</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B118">
<label>118</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Ridge</surname><given-names>PG</given-names></name>, <name name-style="western"><surname>Mukherjee</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Crane</surname><given-names>PK</given-names></name></person-group>, <etal>et al</etal>
<article-title>Alzheimer’s disease: Analyzing the missing heritability</article-title>. <source/>PLoS One<year>2013</year>;<volume>8</volume>:<fpage>e79771</fpage><pub-id pub-id-type="pmid">24244562</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B119">
<label>119</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Gatz</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Reynolds</surname><given-names>CA</given-names></name>, <name name-style="western"><surname>Fratiglioni</surname><given-names>L</given-names></name></person-group>, <etal>et al</etal>
<article-title>Role of genes and environments for explaining Alzheimer disease</article-title>. <source/>Arch Gen Psychiatry<year>2006</year>;<volume>63</volume>:<fpage>168</fpage>–<lpage>74</lpage><pub-id pub-id-type="pmid">16461860</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B120">
<label>120</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Song</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal>
<article-title>Hidden risk genes with high-order intragenic epistasis in Alzheimer’s disease</article-title>. <source/>J Alzheimers Dis<year>2014</year>;<volume>41</volume>:<fpage>1039</fpage>–<lpage>56</lpage><pub-id pub-id-type="pmid">24762948</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B121">
<label>121</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Ridge</surname><given-names>PG</given-names></name>, <name name-style="western"><surname>Hoyt</surname><given-names>KB</given-names></name>, <name name-style="western"><surname>Boehme</surname><given-names>K</given-names></name></person-group>, <etal>et al</etal>
<article-title>Assessment of the genetic variance of late-onset Alzheimer’s disease</article-title>. <source/>Neurobiol Aging<year>2016</year>;<volume>41</volume>:<fpage>200</fpage> e13–<lpage>20</lpage></mixed-citation>
</ref>
<ref id="nlaa024-B122">
<label>122</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Wilson</surname><given-names>RS</given-names></name>, <name name-style="western"><surname>Barral</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>JH</given-names></name></person-group>, <etal>et al</etal>
<article-title>Heritability of different forms of memory in the late onset Alzheimer’s disease family study</article-title>. <source/>J Alzheimers Dis<year>2011</year>;<volume>23</volume>:<fpage>249</fpage>–<lpage>55</lpage><pub-id pub-id-type="pmid">20930268</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B123">
<label>123</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Mez</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Mukherjee</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Thornton</surname><given-names>T</given-names></name></person-group>, <etal>et al</etal>
<article-title>The executive prominent/memory prominent spectrum in Alzheimer’s disease is highly heritable</article-title>. <source/>Neurobiol Aging<year>2016</year>;<volume>41</volume>:<fpage>115</fpage>–<lpage>21</lpage><pub-id pub-id-type="pmid">27103524</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B124">
<label>124</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Beecham</surname><given-names>GW</given-names></name>, <name name-style="western"><surname>Hamilton</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Naj</surname><given-names>AC</given-names></name></person-group>, <etal>et al</etal>
<article-title>Genome-wide association meta-analysis of neuropathologic features of Alzheimer’s disease and related dementias</article-title>. <source/>PLoS Genet<year>2014</year>;<volume>10</volume>:<fpage>e1004606</fpage><pub-id pub-id-type="pmid">25188341</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B125">
<label>125</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Farfel</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Buchman</surname><given-names>AS</given-names></name></person-group>, <etal>et al</etal>
<article-title>Relation of genomic variants for Alzheimer disease dementia to common neuropathologies</article-title>. <source/>Neurology<year>2016</year>;<volume>87</volume>:<fpage>489</fpage>–<lpage>96</lpage><pub-id pub-id-type="pmid">27371493</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B126">
<label>126</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Tropf</surname><given-names>FC</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>SH</given-names></name>, <name name-style="western"><surname>Verweij</surname><given-names>RM</given-names></name></person-group>, <etal>et al</etal>
<article-title>Hidden heritability due to heterogeneity across seven populations</article-title>. <source/>Nat Hum Behav<year>2017</year>;<volume>1</volume>:<fpage>757</fpage>–<lpage>65</lpage><pub-id pub-id-type="pmid">29051922</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B127">
<label>127</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>CC</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>CC</given-names></name>, <name name-style="western"><surname>Kanekiyo</surname><given-names>T</given-names></name></person-group>, <etal>et al</etal>
<article-title>Apolipoprotein E and Alzheimer disease: Risk, mechanisms and therapy</article-title>. <source/>Nat Rev Neurol<year>2013</year>;<volume>9</volume>:<fpage>106</fpage>–<lpage>18</lpage><pub-id pub-id-type="pmid">23296339</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B128">
<label>128</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Farrer</surname><given-names>LA</given-names></name>, <name name-style="western"><surname>Cupples</surname><given-names>LA</given-names></name>, <name name-style="western"><surname>Haines</surname><given-names>JL</given-names></name></person-group>, <etal>et al</etal>
<article-title>Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium</article-title>. <source/>Jama<year>1997</year>;<volume>278</volume>:<fpage>1349</fpage>–<lpage>56</lpage><pub-id pub-id-type="pmid">9343467</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B129">
<label>129</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Ward</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Crean</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Mercaldi</surname><given-names>CJ</given-names></name></person-group>, <etal>et al</etal>
<article-title>Prevalence of apolipoprotein E4 genotype and homozygotes (APOE e4/4) among patients diagnosed with Alzheimer’s disease: A systematic review and meta-analysis</article-title>. <source/>Neuroepidemiology<year>2012</year>;<volume>38</volume>:<fpage>1</fpage>–<lpage>17</lpage><pub-id pub-id-type="pmid">22179327</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B130">
<label>130</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Corder</surname><given-names>EH</given-names></name>, <name name-style="western"><surname>Saunders</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Strittmatter</surname><given-names>WJ</given-names></name></person-group>, <etal>et al</etal>
<article-title>Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families</article-title>. <source/>Science<year>1993</year>;<volume>261</volume>:<fpage>921</fpage>–<lpage>3</lpage><pub-id pub-id-type="pmid">8346443</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B131">
<label>131</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Howie</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Fuchsberger</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Stephens</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal>
<article-title>Fast and accurate genotype imputation in genome-wide association studies through pre-phasing</article-title>. <source/>Nat Genet<year>2012</year>;<volume>44</volume>:<fpage>955</fpage>–<lpage>9</lpage><pub-id pub-id-type="pmid">22820512</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B132">
<label>132</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>van Leeuwen</surname><given-names>EM</given-names></name>, <name name-style="western"><surname>Kanterakis</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Deelen</surname><given-names>P</given-names></name></person-group>, <etal>et al</etal>
<article-title>Population-specific genotype imputations using minimac or IMPUTE2</article-title>. <source/>Nat Protoc<year>2015</year>;<volume>10</volume>:<fpage>1285</fpage>–<lpage>96</lpage><pub-id pub-id-type="pmid">26226460</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B133">
<label>133</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Chaudhury</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Patel</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Barber</surname><given-names>IS</given-names></name></person-group>, <etal>et al</etal>
<article-title>Polygenic risk score in postmortem diagnosed sporadic early-onset Alzheimer’s disease</article-title>. <source/>Neurobiol Aging<year>2018</year>;<volume>62</volume>:<fpage>244.e1</fpage>–<lpage>8</lpage></mixed-citation>
</ref>
<ref id="nlaa024-B134">
<label>134</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Escott-Price</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Bellenguez</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>LS</given-names></name></person-group>, <etal>et al</etal>
<article-title>Gene-wide analysis detects two new susceptibility genes for Alzheimer’s disease</article-title>. <source/>PLoS One<year>2014</year>;<volume>9</volume>:<fpage>e94661</fpage><pub-id pub-id-type="pmid">24922517</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B135">
<label>135</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Naj</surname><given-names>AC</given-names></name>, <name name-style="western"><surname>Jun</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Reitz</surname><given-names>C</given-names></name></person-group>, <etal>et al</etal>
<article-title>Effects of multiple genetic loci on age at onset in late-onset Alzheimer disease: A genome-wide association study</article-title>. <source/>JAMA Neurol<year>2014</year>;<volume>71</volume>:<fpage>1394</fpage>–<lpage>404</lpage><pub-id pub-id-type="pmid">25199842</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B136">
<label>136</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Seshadri</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Fitzpatrick</surname><given-names>AL</given-names></name>, <name name-style="western"><surname>Ikram</surname><given-names>MA</given-names></name></person-group>, <etal>et al</etal>
<article-title>Genome-wide analysis of genetic loci associated with Alzheimer disease</article-title>. <source/>Jama<year>2010</year>;<volume>303</volume>:<fpage>1832</fpage>–<lpage>40</lpage><pub-id pub-id-type="pmid">20460622</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B137">
<label>137</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Bennett</surname><given-names>DA</given-names></name>, <name name-style="western"><surname>Schneider</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Aggarwal</surname><given-names>NT</given-names></name></person-group>, <etal>et al</etal>
<article-title>Decision rules guiding the clinical diagnosis of Alzheimer’s disease in two community-based cohort studies compared to standard practice in a clinic-based cohort study</article-title>. <source/>Neuroepidemiology<year>2006</year>;<volume>27</volume>:<fpage>169</fpage>–<lpage>76</lpage><pub-id pub-id-type="pmid">17035694</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B138">
<label>138</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Mok</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Chow</surname><given-names>TW</given-names></name>, <name name-style="western"><surname>Zheng</surname><given-names>L</given-names></name></person-group>, <etal>et al</etal>
<article-title>Clinicopathological concordance of dementia diagnoses by community versus tertiary care clinicians</article-title>. <source/>Am J Alzheimers Dis Other Demen<year>2004</year>;<volume>19</volume>:<fpage>161</fpage>–<lpage>5</lpage><pub-id pub-id-type="pmid">15214202</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B139">
<label>139</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Schneider</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Aggarwal</surname><given-names>NT</given-names></name>, <name name-style="western"><surname>Barnes</surname><given-names>L</given-names></name></person-group>, <etal>et al</etal>
<article-title>The neuropathology of older persons with and without dementia from community versus clinic cohorts</article-title>. <source/>J Alzheimers Dis<year>2009</year>;<volume>18</volume>:<fpage>691</fpage>–<lpage>701</lpage><pub-id pub-id-type="pmid">19749406</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B140">
<label>140</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Brayne</surname><given-names>C.</given-names></name></person-group>
<article-title>Clinicopathological studies of the dementias from an epidemiological viewpoint</article-title>. <source/>Br J Psychiatry<year>1993</year>;<volume>162</volume>:<fpage>439</fpage>–<lpage>46</lpage><pub-id pub-id-type="pmid">8481734</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B141">
<label>141</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Slooter</surname><given-names>AJ</given-names></name>, <name name-style="western"><surname>Cruts</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kalmijn</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal>
<article-title>Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: The Rotterdam Study</article-title>. <source/>Arch Neurol<year>1998</year>;<volume>55</volume>:<fpage>964</fpage>–<lpage>8</lpage><pub-id pub-id-type="pmid">9678314</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B142">
<label>142</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Leonenko</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Sims</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Shoai</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal>
<article-title>Polygenic risk and hazard scores for Alzheimer’s disease prediction</article-title>. <source/>Ann Clin Transl Neurol<year>2019</year>;<volume>6</volume>:<fpage>456</fpage>–<lpage>65</lpage><pub-id pub-id-type="pmid">30911569</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B143">
<label>143</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Escott-Price</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Baker</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Shoai</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal>
<article-title>Genetic analysis suggests high misassignment rates in clinical Alzheimer’s cases and controls</article-title>. <source/>Neurobiol Aging<year>2019</year>;<volume>77</volume>:<fpage>178</fpage>–<lpage>82</lpage><pub-id pub-id-type="pmid">30851568</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B144">
<label>144</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Escott-Price</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Myers</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Huentelman</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal>
<article-title>Polygenic risk score analysis of Alzheimer’s disease in cases without APOE4 or APOE2 alleles</article-title>. <source/>J Prev Alzheimers Dis<year>2019</year>;<volume>6</volume>:<fpage>16</fpage>–<lpage>9</lpage><pub-id pub-id-type="pmid">30569081</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B145">
<label>145</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Escott-Price</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Myers</surname><given-names>AJ</given-names></name>, <name name-style="western"><surname>Huentelman</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal>
<article-title>Polygenic risk score analysis of pathologically confirmed Alzheimer disease</article-title>. <source/>Ann Neurol<year>2017</year>;<volume>82</volume>:<fpage>311</fpage>–<lpage>4</lpage><pub-id pub-id-type="pmid">28727176</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B146">
<label>146</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Escott-Price</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Shoai</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Pither</surname><given-names>R</given-names></name></person-group>, <etal>et al</etal>
<article-title>Polygenic score prediction captures nearly all common genetic risk for Alzheimer’s disease</article-title>. <source/>Neurobiol Aging<year>2017</year>;<volume>49</volume>:<fpage>214.e7</fpage>–<lpage>11</lpage></mixed-citation>
</ref>
<ref id="nlaa024-B147">
<label>147</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Escott-Price</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Sims</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Bannister</surname><given-names>C</given-names></name></person-group>, <etal>et al</etal>
<article-title>Common polygenic variation enhances risk prediction for Alzheimer’s disease</article-title>. <source/>Brain<year>2015</year>;<volume>138</volume>:<fpage>3673</fpage>–<lpage>84</lpage><pub-id pub-id-type="pmid">26490334</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B148">
<label>148</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Porter</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Burnham</surname><given-names>SC</given-names></name>, <name name-style="western"><surname>Savage</surname><given-names>G</given-names></name></person-group>, <etal>et al</etal>
<article-title>A polygenic risk score derived from episodic memory weighted genetic variants is associated with cognitive decline in preclinical Alzheimer’s</article-title><source/>disease. Front Aging Neurosci<year>2018</year>;<volume>10</volume>:<fpage>423</fpage><pub-id pub-id-type="pmid">30620773</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B149">
<label>149</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>CH</given-names></name>, <name name-style="western"><surname>Fan</surname><given-names>CC</given-names></name>, <name name-style="western"><surname>Mormino</surname><given-names>EC</given-names></name></person-group>, <etal>et al</etal>
<article-title>Polygenic hazard score: An enrichment marker for Alzheimer’s associated amyloid and tau deposition</article-title>. <source/>Acta Neuropathol<year>2018</year>;<volume>135</volume>:<fpage>85</fpage>–<lpage>93</lpage><pub-id pub-id-type="pmid">29177679</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B150">
<label>150</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Desikan</surname><given-names>RS</given-names></name>, <name name-style="western"><surname>Fan</surname><given-names>CC</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name></person-group>, <etal>et al</etal>
<article-title>Genetic assessment of age-associated Alzheimer disease risk: Development and validation of a polygenic hazard score</article-title>. <source/>PLoS Med<year>2017</year>;<volume>14</volume>:<fpage>e1002258</fpage><pub-id pub-id-type="pmid">28323831</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B151">
<label>151</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Sleegers</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Roks</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Theuns</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal>
<article-title>Familial clustering and genetic risk for dementia in a genetically isolated Dutch population</article-title>. <source/>Brain<year>2004</year>;<volume>127</volume>:<fpage>1641</fpage>–<lpage>9</lpage><pub-id pub-id-type="pmid">15130954</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B152">
<label>152</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Chasioti</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Yan</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Nho</surname><given-names>K</given-names></name></person-group>, <etal>et al</etal>
<article-title>Progress in polygenic composite scores in Alzheimer’s and other complex diseases</article-title>. <source/>Trends Genet<year>2019</year>;<volume>35</volume>:<fpage>371</fpage>–<lpage>82</lpage><pub-id pub-id-type="pmid">30922659</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B153">
<label>153</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Szefer</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Lu</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Nathoo</surname><given-names>F</given-names></name></person-group>, <etal>et al</etal>
<article-title>Multivariate association between single-nucleotide polymorphisms in Alzgene linkage regions and structural changes in the brain: Discovery, refinement and validation</article-title>. <source/>Stat Appl Genet Mol Biol<year>2017</year>;<volume>16</volume>:<fpage>349</fpage>–<lpage>65</lpage><pub-id pub-id-type="pmid">29091582</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B154">
<label>154</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Ebbert</surname><given-names>MT</given-names></name>, <name name-style="western"><surname>Ridge</surname><given-names>PG</given-names></name>, <name name-style="western"><surname>Kauwe</surname><given-names>JS.</given-names></name></person-group>
<article-title>Bridging the gap between statistical and biological epistasis in Alzheimer’s disease</article-title>. <source/>Biomed Res Int<year>2015</year>;<volume>2015</volume>:<fpage>1</fpage>–<lpage>7</lpage></mixed-citation>
</ref>
<ref id="nlaa024-B155">
<label>155</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>So</surname><given-names>HC</given-names></name>, <name name-style="western"><surname>Gui</surname><given-names>AH</given-names></name>, <name name-style="western"><surname>Cherny</surname><given-names>SS</given-names></name></person-group>, <etal>et al</etal>
<article-title>Evaluating the heritability explained by known susceptibility variants: A survey of ten complex diseases</article-title>. <source/>Genet Epidemiol<year>2011</year>;<volume>35</volume>:<fpage>310</fpage>–<lpage>7</lpage><pub-id pub-id-type="pmid">21374718</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B156">
<label>156</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Calero</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Gomez-Ramos</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Calero</surname><given-names>O</given-names></name></person-group>, <etal>et al</etal>
<article-title>Additional mechanisms conferring genetic susceptibility to Alzheimer’s disease</article-title>. <source/>Front Cell Neurosci<year>2015</year>;<volume>9</volume>:<fpage>138</fpage><pub-id pub-id-type="pmid">25914626</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B157">
<label>157</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Nazarian</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Kulminski</surname><given-names>AM.</given-names></name></person-group>
<article-title>Evaluation of the genetic variance of Alzheimer’s disease explained by the disease-associated chromosomal regions</article-title>. <source/>J Alzheimers Dis<year>2019</year>;<volume>70</volume>:<fpage>907</fpage>–<lpage>15</lpage><pub-id pub-id-type="pmid">31282417</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B158">
<label>158</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Raghavan</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Tosto</surname><given-names>G.</given-names></name></person-group>
<article-title>Genetics of Alzheimer’s disease: The importance of polygenic and epistatic components</article-title>. <source/>Curr Neurol Neurosci Rep<year>2017</year>;<volume>17</volume>:<fpage>78</fpage><pub-id pub-id-type="pmid">28825204</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B159">
<label>159</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Walter</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Min</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal>
<article-title>The UK10K project identifies rare variants in health and disease</article-title>. <source/>Nature<year>2015</year>;<volume>526</volume>:<fpage>82</fpage>–<lpage>90</lpage><pub-id pub-id-type="pmid">26367797</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B160">
<label>160</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>HF</given-names></name>, <name name-style="western"><surname>Ladouceur</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Greenwood</surname><given-names>CM</given-names></name></person-group>, <etal>et al</etal>
<article-title>Effect of genome-wide genotyping and reference panels on rare variants imputation</article-title>. <source/>J Genet Genomics<year>2012</year>;<volume>39</volume>:<fpage>545</fpage>–<lpage>50</lpage><pub-id pub-id-type="pmid">23089364</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B161">
<label>161</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Pasaniuc</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Rohland</surname><given-names>N</given-names></name>, <name name-style="western"><surname>McLaren</surname><given-names>PJ</given-names></name></person-group>, <etal>et al</etal>
<article-title>Extremely low-coverage sequencing and imputation increases power for genome-wide association studies</article-title>. <source/>Nat Genet<year>2012</year>;<volume>44</volume>:<fpage>631</fpage>–<lpage>5</lpage><pub-id pub-id-type="pmid">22610117</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B162">
<label>162</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>De Jager</surname><given-names>PL.</given-names></name></person-group>
<article-title>The era of GWAS is over – No</article-title>. <source/>Mult Scler<year>2018</year>;<volume>24</volume>:<fpage>258</fpage>–<lpage>60</lpage><pub-id pub-id-type="pmid">29251117</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B163">
<label>163</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Naj</surname><given-names>AC</given-names></name>, <name name-style="western"><surname>Schellenberg</surname><given-names>GD</given-names></name></person-group>, Alzheimer's Disease Genetics Consortium (ADGC). 
<article-title>Alzheimer’s disease genetics C. Genomic variants, genes, and pathways of Alzheimer’s disease: An overview</article-title>. <source/>Am J Med Genet B Genet<year>2017</year>;<volume>174</volume>:<fpage>5</fpage>–<lpage>26</lpage></mixed-citation>
</ref>
<ref id="nlaa024-B164">
<label>164</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Visscher</surname><given-names>PM</given-names></name>, <name name-style="western"><surname>Medland</surname><given-names>SE</given-names></name>, <name name-style="western"><surname>Ferreira</surname><given-names>MA</given-names></name></person-group>, <etal>et al</etal>
<article-title>Assumption-free estimation of heritability from genome-wide identity-by-descent sharing between full siblings</article-title>. <source/>PLoS Genet<year>2006</year>;<volume>2</volume>:<fpage>e41</fpage><pub-id pub-id-type="pmid">16565746</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B165">
<label>165</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Silventoinen</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Sammalisto</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Perola</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal>
<article-title>Heritability of adult body height: A comparative study of twin cohorts in eight countries</article-title>. <source/>Twin Res<year>2003</year>;<volume>6</volume>:<fpage>399</fpage>–<lpage>408</lpage><pub-id pub-id-type="pmid">14624724</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B166">
<label>166</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Silventoinen</surname><given-names>K.</given-names></name></person-group>
<article-title>Determinants of variation in adult body height</article-title>. <source/>J Biosoc Sci<year>2003</year>;<volume>35</volume>:<fpage>263</fpage>–<lpage>85</lpage><pub-id pub-id-type="pmid">12664962</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B167">
<label>167</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Wood</surname><given-names>AR</given-names></name>, <name name-style="western"><surname>Esko</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal>
<article-title>Defining the role of common variation in the genomic and biological architecture of adult human height</article-title>. <source/>Nat Genet<year>2014</year>;<volume>46</volume>:<fpage>1173</fpage>–<lpage>86</lpage><pub-id pub-id-type="pmid">25282103</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B168">
<label>168</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Lango Allen</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Estrada</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Lettre</surname><given-names>G</given-names></name></person-group>, <etal>et al</etal>
<article-title>Hundreds of variants clustered in genomic loci and biological pathways affect human height</article-title>. <source/>Nature<year>2010</year>;<volume>467</volume>:<fpage>832</fpage>–<lpage>8</lpage><pub-id pub-id-type="pmid">20881960</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B169">
<label>169</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Hannan</surname><given-names>AJ.</given-names></name></person-group>
<article-title>Tandem repeats mediating genetic plasticity in health and disease</article-title>. <source/>Nat Rev Genet<year>2018</year>;<volume>19</volume>:<fpage>286</fpage>–<lpage>98</lpage><pub-id pub-id-type="pmid">29398703</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B170">
<label>170</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Treangen</surname><given-names>TJ</given-names></name>, <name name-style="western"><surname>Salzberg</surname><given-names>SL.</given-names></name></person-group>
<article-title>Repetitive DNA and next-generation sequencing: Computational challenges and solutions</article-title>. <source/>Nat Rev Genet<year>2012</year>;<volume>13</volume>:<fpage>36</fpage>–<lpage>46</lpage></mixed-citation>
</ref>
<ref id="nlaa024-B171">
<label>171</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Ebbert</surname><given-names>MTW</given-names></name>, <name name-style="western"><surname>Jensen</surname><given-names>TD</given-names></name>, <name name-style="western"><surname>Jansen-West</surname><given-names>K</given-names></name></person-group>, <etal>et al</etal>
<article-title>Systematic analysis of dark and camouflaged genes reveals disease-relevant genes hiding in plain sight</article-title>. <source/>Genome Biol<year>2019</year>;<volume>20</volume>:<fpage>97</fpage><pub-id pub-id-type="pmid">31104630</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B172">
<label>172</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Rohilla</surname><given-names>KJ</given-names></name>, <name name-style="western"><surname>Gagnon</surname><given-names>KT.</given-names></name></person-group>
<article-title>RNA biology of disease-associated microsatellite repeat expansions</article-title>. <source/>Acta Neuropathol Commun<year>2017</year>;<volume>5</volume>:<fpage>63</fpage><pub-id pub-id-type="pmid">28851463</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B173">
<label>173</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Loureiro</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Oliveira</surname><given-names>CL</given-names></name>, <name name-style="western"><surname>Silveira</surname><given-names>I.</given-names></name></person-group>
<article-title>Unstable repeat expansions in neurodegenerative diseases: Nucleocytoplasmic transport emerges on the scene</article-title>. <source/>Neurobiol Aging<year>2016</year>;<volume>39</volume>:<fpage>174</fpage>–<lpage>83</lpage><pub-id pub-id-type="pmid">26923414</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B174">
<label>174</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Mirkin</surname><given-names>SM.</given-names></name></person-group>
<article-title>The balancing act of DNA repeat expansions</article-title>. <source/>Curr Opin Genet Dev<year>2013</year>;<volume>23</volume>:<fpage>280</fpage>–<lpage>8</lpage><pub-id pub-id-type="pmid">23725800</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B175">
<label>175</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Ionita-Laza</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Makarov</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Consortium</surname><given-names>AAS.</given-names></name></person-group>
<article-title>Scan-statistic approach identifies clusters of rare disease variants in LRP2, a gene linked and associated with autism spectrum disorders, in three datasets</article-title>. <source/>Am J Hum Genet<year>2012</year>;<volume>90</volume>:<fpage>1002</fpage>–<lpage>13</lpage><pub-id pub-id-type="pmid">22578327</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B176">
<label>176</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Blue</surname><given-names>EE</given-names></name>, <name name-style="western"><surname>Bis</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Dorschner</surname><given-names>MO</given-names></name></person-group>, <etal>et al</etal>
<article-title>Genetic variation in genes underlying diverse dementias may explain a small proportion of cases in the Alzheimer’s disease sequencing project</article-title>. <source/>Dement Geriatr Cogn Disord<year>2018</year>;<volume>45</volume>:<fpage>1</fpage>–<lpage>17</lpage><pub-id pub-id-type="pmid">29486463</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B177">
<label>177</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Mez</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Vardarajan</surname><given-names>BN</given-names></name></person-group>, <etal>et al</etal>
<article-title>Association of rare coding mutations with Alzheimer disease and other dementias among adults of European ancestry</article-title>. <source/>JAMA Netw Open<year>2019</year>;<volume>2</volume>:<fpage>e191350</fpage><pub-id pub-id-type="pmid">30924900</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B178">
<label>178</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Bis</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Jian</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Kunkle</surname><given-names>BW</given-names></name></person-group>, <etal>et al</etal>
<article-title>Whole exome sequencing study identifies novel rare and common Alzheimer’s-Associated variants involved in immune response and transcriptional regulation</article-title>. <source/>Mol Psychiatry<year>2018</year>; doi: 10.1038/s41380-018-0112-7</mixed-citation>
</ref>
<ref id="nlaa024-B179">
<label>179</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Preuss</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Capredon</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Wunnemann</surname><given-names>F</given-names></name></person-group>, <etal>et al</etal>
<article-title>Family based whole exome sequencing reveals the multifaceted role of notch signaling in congenital heart disease</article-title>. <source/>PLoS Genet<year>2016</year>;<volume>12</volume>:<fpage>e1006335</fpage><pub-id pub-id-type="pmid">27760138</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B180">
<label>180</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Maffucci</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Bigio</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Rapaport</surname><given-names>F</given-names></name></person-group>, <etal>et al</etal>
<article-title>Blacklisting variants common in private cohorts but not in public databases optimizes human exome analysis</article-title>. <source/>Proc Natl Acad Sci U S A<year>2019</year>;<volume>116</volume>:<fpage>950</fpage>–<lpage>9</lpage><pub-id pub-id-type="pmid">30591557</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B181">
<label>181</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>RC</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Tan</surname><given-names>L</given-names></name></person-group>, <etal>et al</etal>
<article-title>Association of HLA-DRB1 polymorphism with Alzheimer’s disease: A replication and meta-analysis</article-title>. <source/>Oncotarget<year>2017</year>;<volume>8</volume>:<fpage>93219</fpage>–<lpage>26</lpage><pub-id pub-id-type="pmid">29190991</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B182">
<label>182</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Furukawa</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Oka</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Tsuchiya</surname><given-names>N</given-names></name></person-group>, <etal>et al</etal>
<article-title>The role of common protective alleles HLA-DRB1*13 among systemic autoimmune diseases</article-title>. <source/>Genes Immun<year>2017</year>;<volume>18</volume>:<fpage>1</fpage>–<lpage>7</lpage><pub-id pub-id-type="pmid">27829665</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B183">
<label>183</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>ZX</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>HF</given-names></name>, <name name-style="western"><surname>Tan</surname><given-names>L</given-names></name></person-group>, <etal>et al</etal>
<article-title>Effects of HLA-DRB1/DQB1 genetic variants on neuroimaging in healthy, mild cognitive impairment, and Alzheimer’s disease cohorts</article-title>. <source/>Mol Neurobiol<year>2017</year>;<volume>54</volume>:<fpage>3181</fpage>–<lpage>8</lpage><pub-id pub-id-type="pmid">27056075</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B184">
<label>184</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Cree</surname><given-names>BA.</given-names></name></person-group>
<article-title>Multiple sclerosis genetics</article-title>. <source/>Handb Clin Neurol<year>2014</year>;<volume>122</volume>:<fpage>193</fpage>–<lpage>209</lpage><pub-id pub-id-type="pmid">24507519</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B185">
<label>185</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Bertolin</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Querin</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Bozzoni</surname><given-names>V</given-names></name></person-group>, <etal>et al</etal>
<article-title>New FIG4 gene mutations causing aggressive ALS</article-title>. <source/>Eur J Neurol<year>2018</year>;<volume>25</volume>:<fpage>e41</fpage>–<lpage>2</lpage><pub-id pub-id-type="pmid">29464931</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B186">
<label>186</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Osmanovic</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Rangnau</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Kosfeld</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal>
<article-title>FIG4 variants in central European patients with amyotrophic lateral sclerosis: A whole-exome and targeted sequencing study</article-title>. <source/>Eur J Hum Genet<year>2017</year>;<volume>25</volume>:<fpage>324</fpage>–<lpage>31</lpage><pub-id pub-id-type="pmid">28051077</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B187">
<label>187</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Chow</surname><given-names>CY</given-names></name>, <name name-style="western"><surname>Landers</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Bergren</surname><given-names>SK</given-names></name></person-group>, <etal>et al</etal>
<article-title>Deleterious variants of FIG4, a phosphoinositide phosphatase, in patients with ALS</article-title>. <source/>Am J Hum Genet<year>2009</year>;<volume>84</volume>:<fpage>85</fpage>–<lpage>8</lpage><pub-id pub-id-type="pmid">19118816</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B188">
<label>188</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Ren</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Reddy</surname><given-names>JS</given-names></name>, <name name-style="western"><surname>Pottier</surname><given-names>C</given-names></name></person-group>, <etal>et al</etal>
<article-title>Identification of missing variants by combining multiple analytic pipelines</article-title>. <source/>BMC Bioinformatics<year>2018</year>;<volume>19</volume>:<fpage>139</fpage><pub-id pub-id-type="pmid">29661148</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B189">
<label>189</label>
<mixed-citation publication-type="other">NIAGADS. Review and proposed actions for false-positive association results in ADSP case-control data. Available at: <ext-link ext-link-type="uri" xlink:href="https://www.niagads.org/adsp/content/review-and-proposed-actions-false-positive-association-results-adsp-case-control-data">https://www.niagads.org/adsp/content/review-and-proposed-actions-false-positive-association-results-adsp-case-control-data. Accessed December 3, 2019</ext-link></mixed-citation>
</ref>
<ref id="nlaa024-B190">
<label>190</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Schmitt</surname><given-names>FA</given-names></name>, <name name-style="western"><surname>Nelson</surname><given-names>PT</given-names></name>, <name name-style="western"><surname>Abner</surname><given-names>E</given-names></name></person-group>, <etal>et al</etal>
<article-title>University of Kentucky Sanders-Brown healthy brain aging volunteers: Donor characteristics, procedures, and neuropathology</article-title>. <source/>Curr Alzheimer Res<year>2012</year>;<volume>9</volume>:<fpage>724</fpage>–<lpage>33</lpage><pub-id pub-id-type="pmid">22471862</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B191">
<label>191</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Braak</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Braak</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Bohl</surname><given-names>J.</given-names></name></person-group>
<article-title>Staging of Alzheimer-related cortical destruction</article-title>. <source/>Eur Neurol<year>1993</year>;<volume>33</volume>:<fpage>403</fpage>–<lpage>8</lpage><pub-id pub-id-type="pmid">8307060</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B192">
<label>192</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Mirra</surname><given-names>SS.</given-names></name></person-group>
<article-title>The CERAD neuropathology protocol and consensus recommendations for the postmortem diagnosis of Alzheimer’s disease: A commentary</article-title>. <source/>Neurobiol Aging<year>1997</year>;<volume>18</volume>:<fpage>S91</fpage>–<lpage>4</lpage><pub-id pub-id-type="pmid">9330994</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B193">
<label>193</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Suh</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Grando</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Van Deerlin</surname><given-names>VM.</given-names></name></person-group>
<article-title>Validation of a long-read PCR assay for sensitive detection and sizing of C9orf72 hexanucleotide repeat expansions</article-title>. <source/>J Mol Diagn<year>2018</year>;<volume>20</volume>:<fpage>871</fpage>–<lpage>82</lpage><pub-id pub-id-type="pmid">30138726</pub-id></mixed-citation>
</ref>
<ref id="nlaa024-B194">
<label>194</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Cleary</surname><given-names>EM</given-names></name>, <name name-style="western"><surname>Pal</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Azam</surname><given-names>T</given-names></name></person-group>, <etal>et al</etal>
<article-title>Improved PCR based methods for detecting C9orf72 hexanucleotide repeat expansions</article-title>. <source/>Mol Cell Probes<year>2016</year>;<volume>30</volume>:<fpage>218</fpage>–<lpage>24</lpage><pub-id pub-id-type="pmid">27288208</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>